Antiviral Digital Devices

The ADD application enhances immune system response through personalized exercise and VNS tasks, addressing the lack of effective active preventive measures for new viral diseases by delaying and reducing disease peaks in viral outbreaks.

JP2024541932AInactive Publication Date: 2024-11-13S ALPHA THERAPEUTICS INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024524990
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-27
Filing Date
2022-10-27
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current methods for preventing and managing new viral diseases, such as those originating from animals and undergoing mutations, lack effective active preventive measures, as vaccines take years to develop and are ineffective against rapidly spreading pathogens, leading to uncontrolled pandemics with high mortality and significant social and financial losses.

Method used

An antiviral digital device (ADD) application that provides personalized exercise and vagus nerve stimulation (VNS) tasks to enhance the immune system, including moderate exercise, aerobic exercise, and VNS modules to activate natural killer cells, boost T cells, and increase secretory immunoglobulin A (sIgA) secretion, thereby enhancing innate and adaptive immunity.

Benefits of technology

The ADD application effectively delays and reduces the peak onset of viral diseases within healthcare system capacity by strengthening the immune system, increasing NK cell activation, T cell boosting, and mucosal immunity, reducing the severity and spread of infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541932000001_ABST
    Figure 2024541932000001_ABST
Patent Text Reader

Abstract

Systems and methods are provided for maintaining, optimizing or enhancing a subject's immune system. The present disclosure relates to an apparatus for maintaining, optimizing or enhancing a subject's immune system, comprising: a memory for storing a digital application; and a processor configured to execute the digital application to provide at least one of a first exercise module or a first vagus nerve stimulation module, each first module including one or more first tasks for the subject to follow.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims priority to and the benefit of U.S. patent application Ser. No. 17 / 512,579, filed October 27, 2021, the disclosure of which is incorporated herein by reference in its entirety. [Background technology]

[0002] Vaccination is the process of preemptively obtaining immunity to a particular antigen by injecting the human body with a dead or weakened antigen or vaccine that causes the disease. Vaccination has been successfully used to overcome diseases that have plagued humans for a long time (e.g., smallpox, polio, measles, etc.). However, there are cases where vaccination cannot be used. A good example is a new viral disease. A viral disease that originates from an animal can spread to humans and mutate to cause a new viral disease. A new viral disease with a high fatality rate spreads quickly, has severe symptoms, and is not easily cured. This can also pose a new challenge to humans in terms of disease control in that it cannot be easily prevented or cured with existing vaccines or existing antiviral drugs. In the current situation, there is no other practical prevention method other than individuals paying special attention to personal hygiene such as hand hygiene, wearing a mask, social distancing, and self-isolation. However, when the infected population exceeds a certain level and a pandemic begins, the current methods lose their effectiveness. Other than the current personal hygiene and passive preventive measures, there is no active prevention method to control the outbreak of new viral diseases. In addition, it usually takes 5 to 10 years and costs more than $1.5 billion to develop a safe and effective vaccine, and the immune function of the vaccine may not work if the pathogen mutates. Therefore, it is important to manage the individual's immune system to prepare for new variants of the virus in a situation where it is difficult to rely solely on vaccines. [Brief description of the drawings]

[0003] The above and other objects, features and advantages of the present disclosure will become more apparent to those skilled in the art from the detailed description of illustrative embodiments thereof taken in conjunction with the accompanying drawings.

[0004] [Figure 1] 1 shows a graph illustrating the relationship between exercise and upper respiratory tract infection (URTI). [Diagram 2] Illustrate examples of exponential growth, viral transmission, and the golden hour of antiviral defense. [Diagram 3] Illustrates exemplary delayed and reduced disease peaks to control viral diseases within the capabilities of a healthcare system. [Figure 4] This paper illustrates an example of the effect of active antiviral digital immunity (ADI) on reducing the peak incidence of viral disease transmission. [Diagram 5] 1 illustrates an example of an antiviral digital device (ADD) application for personnel interaction. [Figure 6] Illustrates an example of immune response to viral infection with immunological time domains. [Figure 7] Illustrates the first example of a mechanism for antiviral digital immunity (ADI). [Figure 8] Illustrate a second example of the mechanism of antiviral digital immunity (ADI). [Figure 9] Illustrate an example of an ADD application. [Figure 10] FIG. 1 is a first diagram illustrating a modular design for implementing digital therapy with digital devices and applications for maintaining, optimizing or enhancing the immune system. [Figure 11]FIG. 2 is a second diagram illustrating a modular design for implementing digital therapeutics in digital devices and applications for maintaining, optimizing or enhancing the immune system. [Figure 12] The following is an example of the preventive effect of ADI against novel viral infections. [Figure 13] Illustrate an example of an ADD application. [Figure 14] 1 illustrates an exemplary motility suitable for natural killer (NK) cells. [Figure 15] 1 illustrates an exemplary stimulation of the Vagus nerve innervation. [Figure 16] 1 illustrates an exemplary motility suitable for T cells. [Figure 17] 1 illustrates an exemplary motion classifier. [Figure 18] 1 illustrates exemplary task input and practice monitoring for an ADD application. [Figure 19] 1 illustrates an exemplary software schematic according to one embodiment of the present disclosure. [Figure 20] 1 illustrates an exemplary device that can be used in an anti-viral digital device (ADD). [Figure 21] 1 illustrates a flowchart of an exemplary system for maintaining, optimizing or enhancing a subject's immune system, the system including a digital device configured to run a digital application (e.g., an application or "app") for maintaining, optimizing or enhancing a subject's immune system, a healthcare provider portal (e.g., doctor's web) and an administration portal (e.g., administrator's web). [Figure 22] 1 illustrates a flow chart of a service for a digital application of the present disclosure. [Diagram 23] 1 illustrates a flow chart of an exemplary method for determining a target heart rate for a subject. [Figure 24] 1 illustrates a flowchart of an exemplary execution flow for a digital application of the present disclosure. [Diagram 25] 1 illustrates a flow chart of a service for a digital application of the present disclosure. [Figure 26a-b] 1A and 1B respectively illustrate an example execution flow for login verification during a splash process at the start of a digital application of the present disclosure, and an example execution flow for prescription verification during a splash process at the start of a digital application of the present disclosure. [Figure 27] 1 illustrates an exemplary flow chart for a digital application of the present disclosure. [Figure 28] 1 illustrates an exemplary display of a daily module performed by a subject. [Figure 29] 1 illustrates an exemplary series of displays within a moderate exercise module, including displays for exercise preparation, exercise, pause exercise, and end exercise. [Diagram 30] 1 illustrates an exemplary series of displays within the exercise module, including displays for benchmark exercise preparation, benchmark exercise, benchmark exercise pause, and benchmark exercise end. [Diagram 31] 1 illustrates an exemplary benchmark athletic display within the athletic module. [Diagram 32] 1 illustrates a flow chart of an exemplary VNS workflow. [Diagram 33] Illustrated are exemplary displays showing the different types of VNS modules that a subject can perform, including listening to white noise, holding the subject's breath, aroma meditation, experiencing fear, and immersing the subject's face in cold water. [Diagram 34] 1 illustrates an exemplary display for a VNS module, including subject breath-holding. [Diagram 35]Illustrated is an exemplary display showing a settings panel within a digital application, including options for, for example, adjusting the time and / or date, turning push notifications on / off, and viewing terms and conditions. [Diagram 36] 1 illustrates an example execution flow for a healthcare provider portal in the system of the present disclosure. [Figure 37] 1 illustrates an exemplary patient tab on a healthcare provider portal that displays detailed prescription information for a presented patient. [Figure 38] 1 illustrates a flowchart of an exemplary execution flow for an administration portal in the system of the present disclosure. [Figure 39] 1 illustrates an exemplary timeline guide for clinical trial testing. [Diagram 40] 1 is an exemplary graph illustrating adherence rates of experimental groups for an exemplary clinical trial test. [Diagram 41] 1 illustrates an exemplary patient tab on a healthcare provider portal for adding a new patient. [Diagram 42] 1 illustrates a diagram of an exemplary product management system. [Diagram 43] 1 illustrates an exemplary flow chart of an exemplary method of operation for a clinical trial test. [Diagram 44] 1 illustrates an exemplary heart rate sensor. [Diagram 45] 1 illustrates an exemplary heart rate sensor based on the principles of optical blood flow measurement. [Figure 46-51] 1 illustrates a graph illustrating the results of an exemplary clinical trial test. [Figure 52] Graphs illustrating the results (Anova analysis) of NK cell populations between groups at each visit time point V3 (1 week), V4 (5 weeks) and V5 (13 weeks) are shown. [Figure 53]Graphs illustrating the results of naive CD4 T cells between groups at each visit time point (V3, V4 and V5) are shown. [Figure 54] Graphs illustrating central CD4 T cell results between groups at each visit time point (V3, V4 and V5) are shown. [Figure 55] Graphs illustrating effector CD4 T cell results between groups at each visit time point (V3, V4 and V5) are shown. [Figure 56] Graphs illustrating the effect of memory CD4 T cells between groups at each visit time point (V3, V4 and V5) are shown. [Figure 57] Graphs illustrating the results of naive CD8 T cells between groups at each visit time point (V3, V4 and V5) are shown. [Figure 58] Graphs illustrating central CD8 T cell results between groups at each visit time point (V3, V4 and V5) are shown. [Figure 59] Graphs illustrating the effect of CD8 T cells between groups at each visit time point (V3, V4 and V5) are shown. [Figure 60] Graphs illustrating the effect of memory CD8 T cells between groups at each visit time point (V3, V4 and V5) are shown. [Figure 61] Graphs illustrating the results of CD4 Treg (CD25+Foxp3+) cell populations for control and experimental groups at each visit time point (V3, V4 and V5) are shown. [Figure 62] Graphs illustrating the results of CD4 Treg (CD25+Foxp3+) cell populations for the control group, and for the high and low performer groups at each visit time point (V3, V4 and V5) are shown. [Figure 63] Graphs illustrating the results of naive B cells between groups at each visit time point (V3, V4 and V5) are shown. [Figure 64] Graphs illustrating memory B cell results between groups at each visit time point (V3, V4 and V5) are shown. [Figure 65] Graphs illustrating plasma B cell results between groups at each visit time point (V3, V4 and V5) are shown. [Figure 66] Graphs illustrating antibody titer results for H1N1 [A / Guandong-Maonan / SWL1536 / 2019] for the control and experimental groups at each visit time point (V3, V4 and V5) are shown. [Figure 67] Graphs illustrating the antibody titer results for H1N1 [A / Guandong-Maonan / SWL1536 / 2019] for the control group and the high and low performing groups at each visit time point (V3, V4 and V5) are shown. [Figure 68] Graphs illustrating antibody titer results for H3N2 [A / HongKong / 2671 / 2019] for control and experimental groups at each visit time point (V3, V4, and V5) are shown. [Figure 69] Graphs illustrating the antibody titer results for H3N2 [A / HongKong / 2671 / 2019] against the control group and the high and low performing groups at each visit time point (V3, V4 and V5) are shown. [Figure 70] Graphs illustrating antibody titer results for control and experimental groups in B[B / Phuket / 3073 / 2013] at each visit time point (V3, V4 and V5) are shown. [Figure 71] Graphs illustrating the antibody titer results for the control group and the high and low performing groups in B[B / Phuket / 3073 / 2013] at each visit time point (V3, V4 and V5) are shown. [Figure 72] Graphs illustrating antibody titer results for the control and experimental groups at B[B / Washington / 02 / 2019] at each visit time point (V3, V4, and V5) are shown. [Figure 73] Graphs illustrating antibody titer results for the control group and the high and low performing groups at each visit time point (V3, V4, and V5) at B[B / Washington / 02 / 2019] are shown. [Figure 74] Graphs illustrating the change in neutralizing antibody titers for control and experimental groups at weeks 5 (V4) and 13 (V5) compared to baseline (V3). [Fig. 75a-c] Graphs illustrating changes in T and B cells compared to baseline (V2) at 1 week (V3), 5 weeks (V4) and 13 weeks (V5) for control and experimental groups are depicted. [Figure 76] Graphs illustrating changes in natural killer (NK) cells at 1 week (V3), 5 weeks (V4) and 13 weeks (V5) compared to baseline (V2) for control and experimental groups are depicted. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0005] Although the above-identified drawings set forth the presently disclosed embodiments, other embodiments are contemplated, as noted in the discussion. The present disclosure presents exemplary embodiments by way of expression and not of limitation. Numerous other modifications and embodiments can be devised by those skilled in the art that fall within the scope and spirit of the principles of the presently disclosed embodiments.

[0006] BEST MODE FOR CARRYING OUT THE DISCLOSURE Hereinafter, exemplary embodiments of the present disclosure will be described in detail. However, the present disclosure is not limited to the embodiments disclosed below, and may be embodied in various forms. The following embodiments are described to enable those skilled in the art to realize and implement the embodiments of the present disclosure.

[0007] definition Terms such as first, second, etc. may be used to describe various components, but the components are not limited to such terms. Such terms are used only to distinguish one component from another component. For example, a first component may be referred to as a second component, and similarly, a second component may be referred to as a first component, without departing from the scope of the exemplary embodiments. The term "and / or" includes any and all combinations of one or more of the associated stated items.

[0008] Throughout this disclosure, the phrase "at least one of a, b, or c" refers to just a, just b, just c, both a and b, both a and c, both b and c, both a, b, and c, or variations thereof.

[0009] The terms used herein are merely intended to describe certain embodiments and are not intended to limit this exemplary embodiment. The singular forms are intended to include the plural forms unless the context clearly indicates otherwise. As used herein, the terms "comprises", "comprising", "includes" and / or "including" specify the presence of the mentioned features, constants, steps, operations, components, components and / or groups thereof, but can be further understood not to exclude the presence or addition of one or more other features, constants, steps, operations, components, components and / or groups thereof.

[0010] As used herein, the term "about" generally refers to a particular numerical value that is within an acceptable error range as determined by one of ordinary skill in the art, which depends in part on how the numerical value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean a range of ±20%, ±10%, or ±5% of the given numerical value.

[0011] As used herein, the term "antiviral digital device application" generally refers to a health service that can help a subject or group of subjects maintain, optimize, and / or enhance their physical condition by encouraging and suggesting appropriate exercise and vagus nerve or vagus nerve stimulation (VNS). In some embodiments, the exercise can include moderate exercise, aerobic exercise, and / or acute exercise. In certain embodiments, the antiviral digital device application can record the patient's daily condition, provide a moderate and benchmark exercise schedule (e.g., 2-3 times per week), track the patient's heart rate (HR) via a wearable device while the patient exercises (e.g., moderate exercise), provide a target HR for exercise (e.g., moderate exercise), provide activity guidance such as taking deep breaths or listening to white noise to stimulate the vagus nerve, and provide push notifications to encourage the patient to continue using the application.

[0012] As used herein, the term "maintaining, optimizing, or strengthening an immune system" refers to an improvement in a subject's immune system compared to a control subject not exposed to a method, device, or system described herein. In some embodiments, "maintaining" an immune system may be with respect to a subject that is expected to have an immune system that is diminished, for example, with an immune disease. Improvement may be determined based on the amount of NK cells, CD4+ T cells, CD8+ T cells, B cells, pro-inflammatory cytokines IL-6, TNF-a, and IL-1b), anti-inflammatory cytokine (IL-10), and / or IFN-γ, whether antibodies are produced following vaccination against influenza, and / or the onset and severity of upper respiratory tract infection symptoms, as shown in the examples described herein.

[0013] As used herein, the term "moderate exercise" generally refers to exercise (e.g., aerobic exercise) performed at a moderate level (e.g., power walking) such that a target heart rate is maintained.

[0014] As used herein, the term "benchmark exercise" generally refers to performing the same type of exercise for a predetermined period of time to determine a baseline level of fitness for adjusting a target heart rate (e.g., to correspond to moderate exercise). In some embodiments, the benchmark exercise can be performed by the subject at regular intervals (e.g., every 1-2 weeks).

[0015] As used herein, an exercise is considered "completed" if the subject performs the exercise for more than a predetermined period of time (e.g., 5 minutes). If the subject performs the exercise for less than the predetermined period of time, data may not be stored and the exercise is not considered to be finished.

[0016] As used herein, the term "target heart rate" generally refers to a heart rate or heart rate range that corresponds to a particular level of exercise (e.g., moderate exercise) taking into account the age of the subject. Table 1 below shows an initial correspondence between age and target heart rate to achieve low, moderate or vigorous exercise. When checking and prescribing the moderate heart rate range, refer to Table 1 below taking into account the patient's age. Each age group has a moderate heart rate range with different minimum and maximum values. Age group # refers to the oldest of the defined age group. For example, a subject aged 15 to 20 years old belongs to the 20 year old group. The average of the two values ​​can be used as the first target heart rate. For example, for a 21 year old subject who belongs to the 25 year old group, the subject's moderate heart rate range is 122 to 145. The average of the two values ​​is 133.5, and the first target heart rate can be 134 after rounding. Less than 64% of the maximum HR is determined as low intensity. Moderate intensity is defined as 64-76% of maximum HR. Vigorous intensity is defined as greater than 76% of maximum HR.

[0017] Table 1. Target heart rate ranges by age and exercise intensity [Table 1]

[0018] As used herein, the term "vagal nerve stimulation" generally refers to one or more activities that may stimulate the vagus nerve, including, for example, deep breathing, holding the subject's breath, listening to white noise, aroma meditation, immersing the subject's face in cold water, and / or experiencing fear. In certain embodiments, a single VNS module can last for 5 minutes. In certain embodiments, the subject is required to perform a VNS session that lasts more than 10 minutes. Thus, the subject can have two different VNS modules (e.g., performing two sessions that last for 5 minutes each). In certain embodiments, the first VNS module of the day is fixed to deep breathing. In certain embodiments, the two sets of VNS sessions must be performed in consecutive order. If the patient pauses while performing the second set of activities, the records for both the second and first sets of activities may be deleted. In certain embodiments, it is not possible to perform the same set of VNS activities (e.g., the subject cannot select deep breathing for the second set of activities).

[0019] overview Exemplary embodiments of the present disclosure are described in detail below with reference to the accompanying drawings. To facilitate understanding of the present disclosure, the same reference numerals refer to the same components throughout the description of the drawings, and the same components are not described repeatedly.

[0020] As a result of various studies on physical exercise and immune response, it has been reported that NK cells, which are part of the innate immune system and kill cells infected with viruses, are regulated by medium-intensity exercise. Moderate exercise can reduce the risk of infection such as URTIs, low-intensity exercise has no effect, and excessive exercise can increase the possibility of inflammation (see graph below). Regular exercise increases anti-inflammatory cytokines such as interleukin-10 (IL-10) and regulatory T cells, and both long-term and short-term exercise improved the innate and acquired immune response to vaccination.

[0021] In addition to moderate exercise, there are other activities that stimulate the vagus nerve to strengthen the immune system. The vagus nerve is the 10th cranial nerve and is an important component of the parasympathetic branch of the autonomic nervous system that controls the involuntary movements of the heart, lungs, adrenal glands, and digestive tract. It is the most intricately distributed cranial nerve, and unlike other cranial nerves, it extends throughout the body and has a wide distribution. Recent studies have shown that the vagus nerve can regulate cytokine production through the efferent arm of the vagus nerve, which uses neuroimmune communication called the "cholinergic anti-inflammatory pathway." It has been reported that this function of the vagus nerve is applied to rheumatoid arthritis (RA), a chronic inflammatory autoimmune disease, and plays a role in regulating RA. The vagus nerve can be stimulated by actions that do not use electrical signals, such as deep breathing. Deep breathing is a common activity included in many meditation techniques. It stimulates the vagus nerve and influences the parasympathetic nervous system, which can have a positive effect on physical and mental health through meditation.

[0022] Therefore, it is an object of the present invention to help maintain and manage health by inducing immune system enhancement. In one aspect, the present disclosure provides a system and method that allows communication between a patient and a doctor in the form of a mobile application in providing appropriate exercises and activities that stimulate the vagus nerve to enhance the patient's immune system. The patient can record activities in a non-invasive and non-contact manner through a web portal that can be accessed and reviewed by the doctor. In another aspect, the system allows the application to be used only when the doctor prescribes it to the patient for a specific requirement.

[0023] The present disclosure relates to digital therapeutics (hereinafter referred to as DTXs) ​​intended to maintain, optimize or enhance a subject's immune system. The present disclosure also relates to systems that integrate digital therapeutics with one or both of a healthcare provider portal and an administrative portal to maintain, optimize or enhance a subject's immune system. Some embodiments of the present disclosure include inferring mechanisms of action (hereinafter referred to as MOA) in immune health (e.g., immunity to antigens or pathogens) and generating therapeutic and digital therapeutic hypotheses to maintain, optimize or enhance a subject's immune system.

[0024] In some embodiments, the methods described herein activate or increase the generation of natural killer (NK) cells in a subject. In some embodiments, the methods reduce the change in central T cell count in a subject. In some embodiments, the methods reduce the change in effector T cell count in a subject. In some embodiments, the methods reduce the change in effector memory T cell count in a subject. In some embodiments, the methods activate or increase the generation of naive CD4 T cells in a subject. In some embodiments, the naive T cells are activated or increased within one month of providing. In some embodiments, the methods reduce the change in central CD4 T cell count in a subject. In some embodiments, the methods reduce the change in effector CD4 T cell count in a subject. In some embodiments, the methods reduce the change in effector memory CD4 T cell count in a subject. In some embodiments, the methods reduce the change in naive CD8 T cell count in a subject. In some embodiments, the methods reduce the change in central CD8 T cell count in a subject. In some embodiments, the methods reduce the change in effector CD8 T cell count in a subject. In some embodiments, the methods reduce the change in effector memory CD8 T cell count in a subject. In some embodiments, the method activates or increases the generation of CD4 Treg cells in the subject. In some embodiments, the method activates naive B cells for maturation in the subject. In some embodiments, the method increases naive B cells in the subject. In some embodiments, the method increases memory B cells in the subject. In some embodiments, the method decreases plasma B cells in the subject.

[0025] Also described herein are methods and devices for active prevention of viral onset and antiviral digital immunity (ADI). For example, a digital therapeutic module including one or more digital challenges can be generated. The one or more digital challenges can induce at least one of moderate exercise, T cell boosting, B cell maturation, IgA secretion, and natural killer (NK) cell recruitment by moderate exercise in the user's immune system. When exercise is classified into vigorous exercise, moderate exercise, and light exercise, the digital challenge related to NK cell recruitment can include moderate exercise. The challenge related to T cell boosting can include aerobic exercise and / or acute exercise. The challenge related to B cell maturation and IgA secretion can include a VNS-related challenge including at least one of visual, auditory, tactile, gustatory, and olfactory stimuli that increase sIgA secretion. The one or more digital challenges can be provided to the user via a user device.

[0026] Some embodiments disclosed herein relate to an antiviral digital device (ADD) for antiviral digital immunity and active prevention of viral onset. For example, the mechanism of action (MOA) of the host's immune system can be inferred through literature search and expert review of basic science papers and related clinical trial papers on antiviral immunity. The digital device and / or application can transmit a task to boost the host's (and the user of the application) immune system in the digital application based on the MOA, collect the user's practice data on the current task, and also feed back the results of the task-practice set.

[0027] Hereinafter, ADI can refer to antiviral digital immunity with one or more digital challenges used to stimulate antibody production and provide innate and adaptive immunity against one or several viruses. Digital challenges can be prepared from behavioral / environmental codes with modes of action based on innate and adaptive immune system changes that are processed to act as adjuncts of antigenic activity without causing disease.

[0028] Traditional vaccination is a process of preemptively obtaining immunity to a particular antigen by injecting the human body with a dead or weakened disease-causing antigen or vaccine. Vaccination has been successfully used to overcome diseases that have plagued humans for a long time (e.g., smallpox, polio, measles, etc.).

[0029] However, there are cases where vaccination, a key axis of human resistance to disease, cannot be used. A good example is a new viral disease. A viral disease originating from an animal can spread to humans and mutate to cause a new viral disease. A new viral disease with a high fatality rate spreads quickly, has severe symptoms, and is not easily cured. It also poses new challenges to humans in terms of disease management, in that it cannot be easily prevented or cured by existing vaccines or existing antiviral drugs.

[0030] In particular, because of the increased risk of animals to human infection due to the destruction of animal habitats as the human population grows, the activation of thawed viruses as a result of permafrost's melting due to climate change, and increasing globalization facilitating global pandemics, novel viral diseases are predicted to continue to plague humanity in the future as well. Indeed, the outbreak of infectious diseases (e.g., SARS, MERS, COVID-19) from novel mutant coronaviruses is not only a problem in certain regions, but a global problem, causing enormous medical, social and financial losses.

[0031] However, current vaccine technology simply cannot mass-produce vaccines against new viral diseases that spread rapidly.

[0032] Under the current circumstances, there are no effective preventative measures other than individuals paying special attention to personal hygiene, including hand hygiene, wearing masks, and social distancing.

[0033] Responses to the outbreak of new viral diseases, such as isolating infected individuals and recommending self-isolation for contacts, are carried out in the early infection phase before community transmission has begun, based on epidemiological surveys. However, current methods lose their effectiveness once a pandemic has begun beyond a certain level. For example, in the case of COVID-19 in Wuhan, China in 2020, the initial response was insufficient, resulting in a rapid increase in patients that was unmanageable for the responsible local healthcare system, leading to the worst spike in the number of deaths.

[0034] Other than current personal hygiene and passive preventive measures, there are no active prevention methods to control the outbreak of emerging viral diseases. Effective prevention and control measures are urgently needed, especially for healthcare professionals (HCPs) and patient caregivers who continue to be exposed to infectious agents.

[0035] Regardless of time and place, the concept of boosting or providing immunity to prevent disease has been universal. In particular, there is a long history of folk remedies such as consuming certain foods (e.g., red ginseng) or doing certain exercises (e.g., yoga). However, from the perspective of modern science, there is insufficient clinical evidence to support the medical efficacy of the aforementioned foods and exercises.

[0036] Digital therapeutics aim to improve or treat patients' illnesses by providing digital tasks to patients through doctor's prescriptions in an app, regularly monitoring the patient's practice according to the tasks, and collecting the patient's task-practice data. Currently, active research and development on digital therapeutics is underway.

[0037] FIG. 2 illustrates an exemplary exponential growth and transmission of the virus, as well as the golden hour of antiviral defense. The graph in FIG. 2 illustrates the increase in the number of total COVID-19 cases in the United States. Traditionally, management of novel viral diseases for which no vaccine has been developed is based on passive prevention, i.e., preventing physical contact between the novel virus and the host. Examples of passive prevention include wearing masks and practicing hand hygiene at an individual level, as well as practicing social distancing.

[0038] As can be seen from Figure 2, there is a certain time gap between when the danger of the new virus began to be known to society (▼) and when the number of confirmed cases increased sharply (▽). In particular, if active prevention measures that improve the body's immune response are practiced during this period, the spread of the new viral disease can be more effectively controlled.

[0039] FIG. 3 is a diagram illustrating an exemplary delay in outbreak peak and reduction in outbreak peak for controlling viral diseases within the capacity of the healthcare system. In FIG. 3, macroscopic disease control strategies are illustrated in the case of a viral outbreak. The "delay outbreak peak" strategy reduces the speed at which the epidemic spreads, thereby providing time to strengthen the capacity of the healthcare system to prepare for a serious epidemic. Also, the "reduction in peaks of outbreak" strategy helps to mitigate the increase in confirmed cases and manage the epidemic within the capacity of the healthcare system. For the management of new viral diseases, active prevention based on the "reduction in peaks of outbreak" strategy is necessary along with passive prevention based on the established "delay outbreak peak" strategy. However, in the case of new viral diseases for which no vaccine has been developed, the discussion on providing individual immunity for effective active prevention is at a basic level.

[0040] The embodiments disclosed herein may include measures to reduce the prevalence of viruses in application on digital devices (ADDs) without spatiotemporal limitations and financial burdens in virus outbreak situations (ADIs).

[0041] Viral infections show host dependency. This host dependency can be explained in terms of innate immunity due to the genetic factors of the host and acquired immunity resulting from the host's previous experience with pseudoviruses. Infected subjects with acquired immunity tend to overcome viral infection without showing certain symptoms or only show minor symptoms.

[0042] Approaching this realistically, vaccination strategies involving acquired immunity are not effective in the context of novel viral disease outbreaks, since no vaccines have been developed against the current novel viral diseases.

[0043] Host dependency on viruses cannot be explained solely by factors related to the aforementioned innate and acquired immunity. In fact, in the case of highly contagious coronaviruses that infect through the upper respiratory tract mucosa, the elderly are particularly vulnerable. Epidemiological facts can imply that the general immune system of the host with specific organs (spleen, bone marrow and thymus), lymphocytes (B-cells, T-cells and natural killer cells) and antibodies, along with specific mechanisms such as the aforementioned innate and acquired immunity, are important to understand the pathogenesis of novel viral diseases.

[0044] The immune system in the throat and upper respiratory tract, where coronaviruses first come into contact, is called mucosal immunity. Mucosal monocytes, polymorphonuclear leukocytes (PMN), macrophages and natural killer (NK) cells provide the primary defense against the virus. However, if the host immune system cannot provide defense (host factors) or the virus avoids the mucosal immune system, viral infection may spread to other sites, such as the pulmonary alveoli.

[0045] If the host's immune system is collapsed, novel coronavirus infection can cause severe symptoms such as pneumonia, but if the host's immune system is strong, the host may experience few or no symptoms.

[0046] Antiviral MOA of the host's immune system, inferred from a literature search and expert review of basic science articles and related clinical trial articles on antiviral immunity, can include, but are not limited to, increased secretory immunoglobulin A (sIgA) secretion by NK cell activation, T cell boosting and / or mucosal B cell activation. Activated NK cells can nonspecifically kill infected cells, and boosted T cells can specifically kill infected cells. Also, sIgA, an antibody that plays an important role in mucosal immunity, can increase musical immunity. As a result, the host's immune system can be augmented to fight the virus in case of infection without experiencing serious symptoms.

[0047] An embodiment relating to an antiviral digital device is described herein. For example, the embodiment may include, but is not limited to, the following: 1) infer a task useful for enhancing the host's immune system based on the above-mentioned antiviral MOA, and 2) develop a digital device and application including a UI / UX that can communicate the task to the host (and thus the user of the application) and receive feedback.

[0048] Tasks useful for boosting the host's immune system may represent specific host practices or interventions in implementing the aforementioned antiviral MOA. Tasks for implementing the ADI MOA of the present invention may include, but are not limited to, exercise for NK cell recruitment, exercise for T cell boosting, and / or vagus nerve innervation (VNI) for increased sIgA secretion.

[0049] In one aspect, the present disclosure provides a method of maintaining, optimizing or enhancing a subject's immune system, the method comprising providing to the subject by an electronic device an exercise module and / or a vagus nerve stimulation module (VNS), each of the modules including one or more tasks for the subject to follow.

[0050] In some embodiments, the methods described herein activate or increase the generation of natural killer (NK) cells in a subject. In some embodiments, the methods reduce the change in central T cell count in a subject. In some embodiments, the methods reduce the change in effector T cell count in a subject. In some embodiments, the methods reduce the change in effector memory T cell count in a subject. In some embodiments, the methods activate or increase the generation of naive CD4 T cells in a subject. In some embodiments, the naive T cells are activated or increased within one month of providing. In some embodiments, the methods reduce the change in central CD4 T cell count in a subject. In some embodiments, the methods reduce the change in effector CD4 T cell count in a subject. In some embodiments, the methods reduce the change in effector memory CD4 T cell count in a subject. In some embodiments, the methods reduce the change in naive CD8 T cell count in a subject. In some embodiments, the methods reduce the change in central CD8 T cell count in a subject. In some embodiments, the methods reduce the change in effector CD8 T cell count in a subject. In some embodiments, the methods reduce the change in effector memory CD8 T cell count in a subject. In some embodiments, the method activates or increases the generation of CD4 Treg cells in the subject. In some embodiments, the method activates naive B cells for maturation in the subject. In some embodiments, the method increases naive B cells in the subject. In some embodiments, the method increases memory B cells in the subject. In some embodiments, the method decreases plasma B cells in the subject.

[0051] The subject described herein can be a human. The subject can be a human of any age. A particular group of subjects that can be supported includes humans under about 45 years of age, as these subjects can have a more effective response to the VNS described herein. The subject can be about 3, 4, 5, 6, 7, 8, 9, or 10 years of age or older, so that the subject can effectively follow the tasks described herein. In some embodiments, the subject can be a subject who needs to maintain, optimize, or strengthen the immune system. In additional embodiments, the subject can be diagnosed with an immune disease, undergoing chemotherapy, a cancer patient, or a healthy subject.

[0052] The motor module can stimulate the sympathetic nervous system, whereas the VNS module can stimulate the parasympathetic nervous system. Thus, by providing a lag time between the two modules, the effect of each of these two modules can be increased. In certain embodiments, the motor module and the vagus nerve stimulation module are provided with a lag time of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 hours or more and about 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3 hours or less. In certain embodiments, the motor module and the vagus nerve stimulation module are provided with a lag time of preferably about 3 hours to about 10 hours, preferably about 4 hours to about 8 hours, preferably about 4 hours to about 6 hours, preferably about 3 hours to about 6 hours, preferably about 2 hours to 5 hours, preferably about 3 hours to 5 hours, preferably about 8 hours to 10 hours, preferably about 4 hours, preferably about 5 hours, preferably about 6 hours or about 7 hours.

[0053] In certain embodiments, when the exercise module is provided, the exercise module includes one or more tasks to stimulate the subject's sympathetic nervous system. In certain embodiments, when the exercise module is provided, the exercise module includes at least one of an appropriate aerobic exercise and an acute exercise guideline. In certain embodiments, when the exercise module including a moderate exercise task is provided, maintaining, optimizing or enhancing the subject's immune system includes stimulating NK cells. In certain embodiments, when the exercise module including a moderate exercise task is provided, maintaining, optimizing or enhancing the subject's immune system includes stimulating one or more of thymocytes, liver cells, bone marrow cells, tonsil cells, lymph node cells, spleen cells, blood cells, red blood cells, white blood cells, stem cells, B cells, cytotoxic T cells, helper T cells, plasma cells, immunoglobulins, natural killer (NK) cells, neutrophils, monocytes, platelets and dendritic cells. In certain embodiments, when an exercise module including aerobic exercise and / or an acute exercise challenge is provided, maintaining, optimizing or enhancing the immune system of the subject includes T cell boosting. In certain embodiments, when an exercise module including aerobic exercise challenge is provided, maintaining, optimizing or enhancing the immune system of the subject includes expressing CD4+ T cells to activate the immune system. In certain embodiments, when an exercise module including an acute exercise challenge is provided, maintaining, optimizing or enhancing the immune system of the subject includes removing existing T cells to reserve a T cell area for new T cells. In certain embodiments, maintaining, optimizing or enhancing the immune system of the subject includes accelerating the maturation of B-cells and / or the differentiation of B cells into plasma cells. In certain embodiments, maintaining, optimizing or enhancing the immune system of the subject includes increasing the number of reactive cells of the immune system of the subject.

[0054] The problems described in this specification can be embodied and categorized into the following problems that are realized in applications through computer programming:

[0055] Moderate exercise: moderate exercise can recruit NK cells. However, intensive exercise can make the host vulnerable to viral infection. Therefore, exercise hereafter refers to moderate exercise that helps maintain heart rate. Generally, moderate exercise is performed for about 10 minutes every day or 20 minutes 3-4 times per week. In certain embodiments, the method of the present disclosure can include repeating the method twice per week, three times per week, or more than three times per week. Examples of exercise can include, but are not limited to, walking, cycling, yoga, and pilates. Depending on an individual's exercise performance and ability, the intensive / moderate exercise window is different. Therefore, an exercise prescription that reflects the individual's physical ability is necessary (a questionnaire survey or a simple physical test can be conducted to diagnose an individual's exercise performance and physical ability, or data analysis on previous exercise performance can be utilized to diagnose an individual's exercise performance and physical ability.).

[0056] In certain embodiments, moderate exercise is determined based on one or both of age and target heart rate. In certain embodiments, moderate exercise is determined based on ability or disability. In certain embodiments, moderate exercise is determined based on weight. In other embodiments, moderate exercise is determined based on heart rate (HR), repetition maximum (RM), metabolic equivalents (METs), maximum oxygen uptake (VO 2max In certain embodiments, an exercise module is provided that includes an aerobic exercise and / or an acute exercise challenge, and a level of aerobic exercise and / or acute exercise is determined prior to delivery. In certain embodiments, an exercise module is provided that includes an aerobic exercise and / or an acute exercise challenge, and a level of aerobic exercise and / or acute exercise is determined based on at least one of HR, RM, METs, VO 2max It is determined based on at least one of the following: / VO2R, or RPE.

[0057] In certain embodiments, moderate exercise for a subject who is about 15 years old includes a target heart rate of about 126 to about 150 bits per minute (bpm), moderate exercise for a subject who is about 20 years old includes a target heart rate of about 124 to about 147 bpm, moderate exercise for a subject who is about 25 years old includes a target heart rate of about 122 to about 145 bpm, moderate exercise for a subject who is about 30 years old includes a target heart rate of about 120 to about 142 bpm, moderate exercise for a subject who is about 35 years old includes a target heart rate of about 117 to about 139 bpm, moderate exercise for a subject who is about 40 years old includes a target heart rate of about 115 to about 137 bpm, moderate exercise for a subject who is about 45 years old includes a target heart rate of about 113 to about 134 bpm, and moderate exercise for a subject who is about 50 years old includes a target heart rate of about 111 to about 132 bpm. moderate exercise for a subject about 55 years old includes a target heart rate of about 109 to about 129 bpm, moderate exercise for a subject about 60 years old includes a target heart rate of about 107 to about 127 bpm, moderate exercise for a subject about 65 years old includes a target heart rate of about 105 to about 124 bpm, and moderate exercise for a subject about 70 years old includes a target heart rate of about 102 to about 122 bpm. moderate exercise for an approximately 75 year old subject includes a target heart rate of about 100 to about 119 bpm, moderate exercise for an approximately 80 year old subject includes a target heart rate of about 98 to about 117 bpm, moderate exercise for an approximately 85 year old subject includes a target heart rate of about 96 to about 114 bpm, and moderate exercise for an approximately 95 year old subject includes a target heart rate of about 92 to about 109 bpm.

[0058] In certain embodiments, the target heart rate is determined based at least in part on feedback from exercise performed prior to the provision. It is contemplated that subjects who exercise (e.g., exercise on a daily basis) may have a higher target heart rate to experience moderate exercise than subjects who do not exercise regularly. Similarly, it is contemplated that subjects who are healthy (e.g., not physically disabled) may have a higher target heart rate to experience moderate exercise than subjects who are physically disabled. In certain embodiments, an increase in the subject's heart rate by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 bpm or more and about 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 bpm or less compared to the target heart rate for a moderate exercise module will trigger a decrease in the target heart rate for a subsequent moderate exercise module. In certain embodiments, a decrease in the subject's heart rate by more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 bpm and by no more than about 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 bpm compared to the target heart rate for a moderate exercise module will trigger an increase in the target heart rate for a subsequent moderate exercise module.

[0059] Aerobic and / or acute exercise: Aerobic and / or acute exercise can boost T cells. Stimulation by aerobic exercise can generate a favorable immune environment for young T cells, and acute exercise can help secure the T cell area for young T cells.

[0060] In some embodiments, the same exercise challenge can be provided simultaneously as moderate, acute and / or aerobic exercise challenges. In certain embodiments, the exercise modules described herein include at least one exercise challenge for simultaneous aerobic exercise and acute exercise. In certain embodiments, the one or more challenges include challenges for resistance exercise, simultaneous exercise and / or benchmark exercise. In certain embodiments, the benchmark exercise includes one or more selected from the group consisting of jumping jacks, squats, and push-ups. In certain embodiments, the method further includes repeating the benchmark exercise at least once in succession, at least twice in succession, at least three times in succession, at least four times in succession, at least five times in succession, at least six times in succession, at least seven times in succession, at least eight times in succession, at least nine times in succession, or at least ten times in succession.

[0061] In certain embodiments, the one or more tasks include one or more tasks for walking, cycling, aerobic dancing, and / or swimming.It is contemplated that a particular exercise may be suitable for low, moderate, or vigorous exercise (e.g., depending on the intensity at which the subject exercises).For example, slow running (e.g., 2 miles per hour) may be suitable for low intensity exercise, whereas faster running (e.g., 3-5 miles per hour) may be suitable for moderate or vigorous exercise.

[0062] Vagus nerve stimulation (VNS): VNS can increase sIgA secretion. There are many immune cells near the gastrointestinal mucosa. After B cells mature through the VNS mucosal lymphoid follicles and migrate to the mucosal site of action, they are expressed as plasma cells and increase the secretion of sIgA. VNS can consist of stimulation of the senses, such as a 10-minute concentrated cold compress or deep breathing.

[0063] In certain embodiments, when a vagus nerve stimulation module is provided as described herein, the vagus nerve stimulation module includes one or more tasks for stimulating the subject's parasympathetic nervous system. In certain embodiments, a vagus nerve stimulation module is provided and the vagus nerve stimulation module includes at least one task selected from the group consisting of sensory stimulation tasks related to sight, sound, touch, taste, and smell.

[0064] In some embodiments, instructions can be included for practicing various exercises and VNS for boosting immunity without application intervention (e.g., training, exercise manuals, and YouTube videos). In other embodiments, instructions can be provided for communicating exercise and VNS challenges through a simple application without MOA-based evidence or MOA-based clinical trial results (e.g., health application).

[0065] In certain embodiments, the vagus nerve stimulation module described herein includes one or more sensory stimulation tasks for vision, and the one or more sensory stimulation tasks for vision include one or more tasks for viewing one or more figures to stimulate the autonomic nervous system. In certain embodiments, the electronic device receives and displays the figures. In certain embodiments, the pictures include one or more images to induce fear in the subject. In certain embodiments, the vagus nerve stimulation module includes one or more sensory stimulation tasks for hearing, and the one or more sensory stimulation tasks for hearing include one or more tasks for listening to one or more sounds to induce fear or relaxation. In certain embodiments, the one or more sounds to induce relaxation include white noise. In certain embodiments, the electronic device receives and plays sounds. In certain embodiments, the vagus nerve stimulation module includes one or more sensory stimulation tasks for touch, and the one or more sensory stimulation tasks for touch include one or more tasks for abdominal breathing, breathing rate control, breath holding, cold compresses, cold water dipping, coughing, and skin massage. In certain embodiments, the vagus nerve stimulation module includes one or more sensory stimulation tasks for touch, and the one or more sensory stimulation tasks for touch include one or more tasks for controlling respiration rate. In certain embodiments, the respiration rate can be 3 breaths per minute, 4 breaths per minute, 5 breaths per minute, 6 breaths per minute, 7 breaths per minute, 8 breaths per minute, 9 breaths per minute, 10 breaths per minute, 15 breaths per minute, or more than 20 breaths per minute. In certain embodiments, the vagus nerve stimulation module includes one or more sensory stimulation tasks for smell, and the one or more sensory stimulation tasks for smell include one or more tasks for relaxation. In certain embodiments, the electronic device is configured to emit a scent for aromatherapy.

[0066] In certain embodiments, the motor module is provided before the vagus nerve stimulation module. The motor module can be provided after the vagus nerve stimulation module.

[0067] The embodiments described herein can extend the effect of boosting the immune system beyond viral diseases to other infectious diseases, including upper respiratory tract (UR) as well as Gastrointestinal (GI) infections.

[0068] FIG. 4 illustrates an exemplary active antiviral digital immunity (ADI) effect on the reduction of the disease peak in a viral disease transmission. In FIG. 4, the activation of ADI (antiviral digital immunity) by ADD (antiviral digital device) is shown along with the progression of the virus disease. Hospitals and health authorities analyze the symptoms and infection routes of infected patients after a mutant virus from an animal infects a human. The responsible health authorities judge the analyzed results and can inform the society of the risk, nature, symptoms, etc. of the disease and enter into passive prevention of the disease. Scenario 1 I is a graph showing the increase in the number of patients if no preemptive measures against the spread of the infection are taken. As mentioned in FIG. 2, after the alarm, the number of patients increases sharply after a certain amount of time has passed. Scenario 2 II is a graph showing the increase in the number of patients when passive prevention methods such as wearing masks, practicing hand hygiene, and social distancing are used. It is observed that the virus disease peak is delayed for a certain time.

[0069] Scenario 3, III, is a graph showing the increase in the number of patients when active prevention methods such as ADI activation by ADD are used together with passive prevention methods. Not only is a delay in the viral disease peak expected, but also a reduction in the disease peak is expected. ADD-based ADI activation improves individual immunity by performing specific tasks using the application during the golden hour of disease control, i.e., between the time when the alert is issued and the time when mass infection cases increase sharply. Ultimately, this serves to manage new viral diseases within the capacity of the healthcare system by increasing the proportion of asymptomatic cases and decreasing the proportion of severely symptomatic cases.

[0070] FIG. 5 is a diagram illustrating an exemplary antiviral digital device (ADD) application for personal interaction. FIG. 5 shows the process of ADD activating an individual's ADI. ADD can be realized in an application of a digital device such as a desktop computer, a laptop computer, a tablet, or a smartphone. A user can download an app, receive challenges through an ADD UI, and practice them. The user's practice can provide feedback to the application by various means, such as login / logout information, user ratings and reviews / records, and passive data collection by sensors. This challenge-practice feedback loop can improve the user's immune provision and improve the user's resistance to infection. Looking at a more specific response of the immune system to ADD, the process of challenge-practice feedback can improve the user's NK cell activation, increase the secretion of slgA, and boost T cells. ADD can be designed based on the MOA that induces the above-mentioned immune system response. As a result, the user's practiced challenges can calculate an immune provision to an individual, and the active prevention purpose is achieved.

[0071] FIG. 6 illustrates an exemplary immune response to viral infection in immunological time domains. FIG. 6 shows the sequential response of the host immune system in a typical viral infection. Virus-induced URT (upper respiratory tract) / GI (gastrointestinal) infection can immediately trigger phagocytosis of the phagocytes and NK cells of the innate immune system. Viruses that have avoided or neutralized this step can be attacked by the viral antigen specific acquired immune system linked to APC (antigen processing cell)-CD4+ T-cells and CD8+ T killer cells. This process can occur within 3-4 days after infection, and the overwhelming cytokine response in this process produces a cytokine storm. A portion of the CD4+ T cells can activate B cells to induce antibody secreting cells that generate viral antigen-specific antibodies. Some B cells then develop into memory B cells with the ability to produce antibodies against specific antigens, and subsequently acquire acquired immunity against the infection. This process may take longer than the two previous processes. After the immunity of the innate and acquired immune systems overcomes the viral activity, the host may become mildly symptomatic or asymptomatic. Conversely, if the activity of the virus overwhelms the immunity of the innate and acquired immune systems, the host may become severely symptomatic.

[0072] 7 and 8 are diagrams illustrating an exemplary mechanism of antiviral digital immunity (ADI). In FIG. 7 and FIG. 8, a mechanism by which ADD generates a user's ADI is illustrated. The ADI task box represents a series of actions that the user practices through the tasks related to ADD, and the immunological event box provides the results of the immune system and user's actions in FIG. 6. Exercise suitable for NK cells can activate NK cells and nonspecifically kill infected cells through the innate immune system. Aerobic and acute exercise can help to secure T cell areas for young T cells and boost T cells in case of infection. Finally, innervation of the vagus nerve can activate B cells in the mucosa and increase the secretion of slgA, which also plays an important role in mucosal immunity, creating an environment in which nonspecific antigen immune elimination can be effectively performed.

[0073] Thus, an ADI can be defined that enhances the host's immunity to the virus through user challenge with the ADD.

[0074] FIG. 9 illustrates an example of an ADD application. The activity program of the application of the present disclosure can be composed of two types, called external and internal functional activities. First, an external functional activity can be requested to be performed for 30 minutes twice a week (including 5 minutes each of warming-up and cooling-down activities). Upon entering the external functional activity, a subject-adapted target heart rate (HR) range can be presented on the mobile screen. The target HR range can be estimated as {(207-0.7Хage)-resting HR}×intensity level(%)+resting HR. HR can be detected by a wearable device. The participant's heart rate can be transferred in real time to the application of the present disclosure, which can display the current HR on the screen and visual feedback on whether the activity level is within the target range. To complete the activity, the subject must actively move his / her body at a level that allows him / her to reach the target HR zone, which induces physical activity at a moderate intensity level. Second, the internal function activity can consist of five static activities, such as deep breathing, two of which must be performed for 10 minutes each day. Each activity may take five minutes, and the two activities must be performed consecutively so that the activity is recorded as completed.

[0075] FIG. 10 is a first diagram illustrating a modular design for implementing digital therapy in digital devices and applications for maintaining, optimizing, or enhancing the immune system. As illustrated in FIG. 10, when a therapeutic hypothesis based on the mechanism of action of the immune system is generated, target neurohumoral factors (e.g., NK cells, T cells, cytokines, B cells / secretory lg, B cells / mucosal immunity, etc.) can be inferred. Imaginary parameters can be utilized to match specific tasks to the regulation of such neurohumoral factors. Modules required for immune system enhancement can be inferred using a "neurohumoral factor-imaginary parameter module" interrelationship. Each of the modules is described in more detail in the form of a modular task with reference to FIGS. 15-16, as described below. In this case, each of the modules is a basic design unit for a digital therapy implemented in a digital device or application, and is a collection of specific tasks. Specifically, referring to FIG. 10, the neurohumoral factors inferred based on the mechanism of action in the immune system and the therapeutic hypothesis for the immune system can be NK cells, T cells, cytokines, B cells / secretory Ig, or B cells / mucosal immunity, etc. The control of each of the neurohumoral factors can correspond to a digital therapeutic module that uses a behavior (moderate exercise, aerobic exercise, cold compress, deep breathing, etc.) as a virtual parameter. A specific digital task for each module can be generated based on the converted module. In this case, the digital task can include a behavior module (e.g., NK cell action task, T cell action task, cytokine action task, B cell (systemic) action task, B cell (local) action task, etc.), which can be output by the monitor. However, the modules are presented merely as examples and are not intended to be limited to the modules according to the present disclosure.

[0076] FIG. 11 is a second diagram illustrating a modular design for implementing digital therapeutics in digital devices and applications for maintaining, optimizing or enhancing the immune system.

[0077] FIG. 12 illustrates an example of an exemplary ADI preventive effect against novel viral infection. When the risk of novel viral disease is alerted to society, ADI can improve an individual's immune provision by stimulating and activating the individual's immune system until viral infection increases sharply. Such strengthening of an individual's immune provision can increase the patient's immunity so that the patient experiences only minor symptoms when infected and easily recovers from the infection.

[0078] Figure 13 is a diagram illustrating an exemplary ADD application. Figure 13 clearly shows the NK cell task, vagus nerve innervation task, and T cell task introduced in Figure 8, which are further reflected in the application plan. Application programming and application design based on the plan can successfully realize the ADD application.

[0079] FIG. 14 is a diagram illustrating an exemplary exercise suitable for natural killer cells (NK cells). Exercise suitable for NK cells may represent moderate exercise (20 minutes, 3-4 times a week) of 10 minutes per day that helps maintain heart rate. For example, it may include, but is not limited to, walking, cycling, yoga, and / or pilates. It is preferable to classify an individual's physical strength into three categories based on their physical fitness, and use the classification to prescribe exercise.

[0080] In order to exercise in a way that is suitable for NK cells, it may be important to practice moderate exercise. As shown in Figure 14, no amount of exercise or intense exercise can weaken the immune system.

[0081] FIG. 15 illustrates an exemplary stimulation of the innervation of the vagus nerve. In FIG. 15, a table summarizing various means for stimulating the vagus nerve is illustrated. Vagus nerve stimulation can be performed, for example, by involving visual, auditory, tactile, taste and smell sensations, molecules, etc. Vagus nerve innervation tasks can include, but are not limited to, cold compresses, deep breathing, abdominal breathing, listening to music, watching movies, etc.

[0082] FIG. 16 illustrates an exemplary exercise suitable for T cells. "Acute exercise" may be defined as a single bout of exercise. Acute exercise may affect circulation and cause blood to move to tissues that are more likely to come into contact with infected cells. The acute effect of exercise may also stimulate the mobilization of senescent immune cells and reserve T cell areas for young T cells. As illustrated in FIG. 16, exercise suitable for T cells may include, but is not limited to, both aerobic and anaerobic exercise. However, it is noted that chronic exercise may be a safe mode of intervention to improve the efficacy of flu vaccination in the elderly population without adverse side effects.

[0083] 17 is a diagram illustrating exemplary exercise classifiers. Various exercise classifiers are possible, examples of which include, but are not limited to, heart rate (HR), repetition maximum (RM), metabolic equivalents (METs), maximum oxygen uptake (VO 2max ) / oxygen reserve (VO2R) or rate of perceived exertion (RPE).

[0084] Athletic performance may vary from user to user depending on a variety of factors, such as age, gender, athletic ability, exercise history, and underlying diseases (eg, cardiovascular disease, hypertension, diabetes).

[0085] ADD tasks that can induce ADI can cover an “Exercise Classifier” that suggests personalized exercise intensity and repetitions.

[0086] The Exercise Classifier can be operated as follows to provide personalized exercise prescriptions. For example, 1) when physically visiting a hospital: HCPs (healthcare professionals) judge the user's exercise performance based on pre-visit or physical test data before prescribing / recommending ADD; 2) when using an activity tracking device (e.g., HR detector): an algorithm judges the user's exercise performance based on the user's activity data; 3) AI judges the user's exercise performance based on the analysis of long-term tracing data (big data); 4) when self-management: Since there is no HCP or assistive device, a questionnaire survey in the RPE format can be used.

[0087] FIG. 18 is a diagram illustrating an exemplary task input and performance monitoring of an ADD application. In FIG. 18, various combinations of input and monitoring of the ADD app are described. Task input can be provided to the user by visual display, auditory narration, touch / vibration, etc. Performance can be classified into three categories: 1) application login / out information; 2) activity data generated by the user's typing or recording; and 3) passive data collected by sensors. Sensors for passive data collection can include activity trackers, automatic recorders, bio-feedback devices, etc.

[0088] FIG. 19 illustrates an exemplary software schematic according to an embodiment of the present disclosure. [1] Data of the subject's stable body signs (e.g., heart rate, etc.) can be processed by the application's software with basic information. [2] The application's software algorithm processes the body signs representing customized antiviral immunity boosting range activity (e.g., an embodiment of the present disclosure uses heart rate as the body sign and determines if the stabilized heart rate is 80, then individualizes the heart rate representing immune boosting range activity). [3] The software transmits the determined antiviral immunity boosting range body signs to the subject through the application to allow the subject to progress through the program within this range, and also collects data on the subject's activity time, activity level, and the relationship between activity and immune boosting range body signs to provide intervention through feedback to the subject. [4] The software can transmit the subject's activity data to the sensor through the application. [5] The software can further forward all subject data collected by the sensor to the application to check the accuracy of the data. [6] The application software can process the data collected through the sensors in real time and further transfer the data to the sensors and server.[7][8] The software can transmit the data through the server to the web, through which health professionals can monitor the subject's performance and safety, and can communicate with the subject and provide feedback to the subject, such as advice and encouragement.

[0089] 20 is a system diagram illustrating an example device 1400 that may be used to provide antiviral digital immunity (ADI) that may be used in combination with any other embodiment described herein. As illustrated in FIG. 20, the apparatus 1400 may include, among other things, a processor 1418, a transceiver 1420, a transmit / receive element 1422, a speaker / microphone 1424, a keypad 1426, a display / touchpad 1428, a non-portable memory 1430, a portable memory 1432, a power source 1434, a Global Positioning System (GPS) chipset 1436, and / or other peripherals 1438. It is understood that the device 1400 may include any sub-combination of the above-mentioned components while remaining consistent with an embodiment. By way of example, device 1400 may include a mobile device, user equipment (UE), mobile station, fixed or mobile subscriber unit, subscription-based unit, phasor, mobile phone, personal digital assistant (PDA), smartphone, laptop, netbook, personal computer, wireless sensor, hotspot or Mi-Fi device, Internet of Things (IoT) device, watch or other wearable, head mounted display (HMD), automobile, drone, medical device and application (e.g., remote surgery), industrial device and application (e.g., robots and / or other wireless devices operating in industrial and / or automated processing chain contexts), consumer electronic device, device operating in commercial and / or industrial wireless networks, etc.

[0090] The processor 1418 can be a general purpose processor, a special purpose processor, an existing processor, a digital signal processor (DSP), multiple microprocessors, one or more microprocessors in conjunction with a DSP core, a controller, a microcontroller, an application specific integrated circuit (ASIC), a field programmable gate array (FPGA), any other type of integrated circuit (IC), a state machine, etc. The processor 1418 can perform data processing, power control, input / output processing, sensor date processing, and / or any other function that enables the device 1400 to provide an antiviral digital device. The processor 1418 can be coupled to a transceiver 1420, which can be coupled to a transmit / receive element 1422. Although FIG. 20 illustrates the processor 1418 and the transceiver 1420 as separate components, it can be understood that the processor 1418 and the transceiver 1420 can be integrated together in an electronic package or chip.

[0091] The transmit / receive element 1422 can be configured to transmit data to or receive data from a server located at a medical institution. For example, a medical problem from a doctor / sensed medical information from a user can be received / transmitted from / to the server through the base station via the wireless interface 1416. In one embodiment, the transmit / receive element 1422 can be an antenna configured to transmit and / or receive RF signals. In an embodiment, the transmit / receive element 1422 can be an emitter / detector configured to transmit and / or receive, for example, IR, UV, or visible light signals. In yet another embodiment, the transmit / receive element 1422 can be configured to transmit and / or receive both RF and light signals. It can be understood that the transmit / receive element 1422 can be configured to transmit and / or receive any combination of wireless signals. The transceiver 1420 can be configured to modulate signals transmitted by the transmit / receive element 1422 and demodulate signals received by the transmit / receive element 1422.

[0092] The processor 1418 of the device 1400 may be coupled to and may receive user input data from a speaker / microphone 1424, a keypad 1426, a display / touchpad 1428 (e.g., a liquid crystal display (LCD) display unit or an organic light emitting diode (OLED) display unit), and / or peripherals 1438 (e.g., a sensor or a digital camera). The processor 1418 may also output user data or digital challenges to the speaker / microphone 1424, the keypad 1426, the display / touchpad 1428, and / or the peripherals 1438. The processor 1418 may also access information from and store data in any type of suitable memory, such as the non-portable memory 1430 and / or the portable memory 1432. The non-portable memory 1430 may include a random-access memory (RAM), a read-only memory (ROM), a hard disk, or any other type of memory storage device. The portable memory 1432 may include a Subscriber Identity Module (SIM) card, a memory stick, a secure digital (SD) memory card, etc. In other embodiments, the processor 218 may access information from and store data in memory that is not physically located on the device 1400, such as a server or a home computer (not shown).

[0093] The processor 1418 can receive power from the power source 1434 and can be configured to distribute and / or control the power to other components of the device 1400. The power source 1434 can be any suitable device for providing power to the device 1400. For example, the power source 1434 can include one or more dry cell batteries (e.g., nickel cadmium (NiCd), nickel zinc (NiZn), nickel metal hydride (NiMH), lithium ion (Li-ion), etc.), solar cells, fuel cells, etc.

[0094] The processor 1418 may also be coupled to a GPS chipset 1436, which may be configured to provide location information (e.g., longitude and latitude) regarding the current location of the device 1400. In addition to or in lieu of the GPS chipset 1436 information, the device 1400 may receive location information over the wireless interface 1416 from a base station and / or may determine its location based on the timing of signals received from two or more nearby base stations. It may be understood that the device 1400 may obtain location information by any suitable position-determining method while remaining consistent with an embodiment.

[0095] The processor 1418 can be further coupled to other peripherals 238 that can include one or more software and / or hardware modules providing additional features, functionality, and / or wired or wireless connectivity. For example, the peripherals 238 can include an accelerometer, an e-compass, a satellite transceiver, a digital camera (for photos and / or videos), a universal serial bus (USB) port, a vibration device, a television transceiver, a hands-free headset, a Bluetooth® module, a frequency modulation (FM) radio unit, a digital music player, a media player, a video game player module, an Internet browser, a virtual reality and / or augmented reality (VR / AR) device, an activity tracker, and the like. The peripherals 1438 can include one or more sensors. The sensors can be one or more of a gyroscope, an accelerometer, a Hall effect sensor, a magnetometer, an orientation sensor, a proximity sensor, a temperature sensor, a time sensor; a geolocation sensor, an altimeter, a light sensor, a touch sensor, a magnetometer, a barometer, a gesture sensor, a biosensor, a humidity sensor, and the like.

[0096] In one aspect, the present disclosure provides a method of maintaining, optimizing or enhancing a subject's immune system, the method comprising providing to the subject by an electronic device a first exercise module and / or a first vagus nerve stimulation (VNS) module, each of the first modules including one or more first tasks to be followed by the subject. In a particular embodiment, the method further comprises providing to the subject by an electronic device a second exercise module and / or a second vagus nerve stimulation module, each of the second modules including one or more second tasks, the electronic device (i) including a sensor for sensing the subject's compliance with the first tasks of the first module, (ii) transmitting compliance information to a server based on the compliance, and (iii) receiving one or more second tasks from the server based on the compliance information.

[0097] In some embodiments, the methods described herein activate or increase the generation of natural killer (NK) cells in a subject. In some embodiments, the methods reduce the change in central T cell count in a subject. In some embodiments, the methods reduce the change in effector T cell count in a subject. In some embodiments, the methods reduce the change in effector memory T cell count in a subject. In some embodiments, the methods activate or increase the generation of naive CD4 T cells in a subject. In some embodiments, the naive T cells are activated or increased within one month of providing. In some embodiments, the methods reduce the change in central CD4 T cell count in a subject. In some embodiments, the methods reduce the change in effector CD4 T cell count in a subject. In some embodiments, the methods reduce the change in effector memory CD4 T cell count in a subject. In some embodiments, the methods reduce the change in naive CD8 T cell count in a subject. In some embodiments, the methods reduce the change in central CD8 T cell count in a subject. In some embodiments, the methods reduce the change in effector CD8 T cell count in a subject. In some embodiments, the methods reduce the change in effector memory CD8 T cell count in a subject. In some embodiments, the method activates or increases the generation of CD4 Treg cells in the subject. In some embodiments, the method activates naive B cells for maturation in the subject. In some embodiments, the method increases naive B cells in the subject. In some embodiments, the method increases memory B cells in the subject. In some embodiments, the method decreases plasma B cells in the subject.

[0098] In another aspect, the server receives one or more second challenges from an external reviewer. In some embodiments, the external reviewer includes a medical professional (e.g., a health care provider or doctor). In some embodiments, the external reviewer includes an artificial intelligence (AI). The term "artificial intelligence" can refer to the intelligence exhibited by a machine. In computer science, an ideal "intelligent" machine is a flexible, rational agent that recognizes its environment and takes actions that maximize the chances of success at a specific goal (e.g., maintaining, optimizing, or enhancing a subject's immune system). Colloquially, the term "artificial intelligence" is applied when a machine mimics the "cognitive" functions that humans associate with other human minds, such as "learning" and "problem solving." The term artificial intelligence can refer to algorithms that can apply learning techniques to multiple types of information (e.g., physiological information, additional information, and an individual's medical history).

[0099] In some embodiments, the digital device includes a sensor, the sensor including one or more of the following: a camera, an accelerometer, a magnetometer, a light sensor, a microphone, a proximity sensor, a touch sensor, a gyroscope, a Global Positioning System (GPS) sensor, an ambient light sensor, a fingerprint sensor, a pedometer, a heart rate sensor, and a thermometer. In some embodiments, the sensor includes a touch sensor, and the subject provides the adherence information to the electronic device using the touch sensor. In certain embodiments, the digital device is selected from the group consisting of a smartphone, a smartwatch, smart jewelry, and a head mounted display.

[0100] Based on the pathogenic mechanism and treatment hypothesis and the digital treatment hypothesis for maintaining, optimizing, and enhancing the immune system of the subject, the doctor (second user) can prescribe a digital therapeutic agent to the patient, which is realized in an application and a digital device for processing the maintaining, optimizing, and enhancing the immune system of the subject. In this case, the digital task generator is a device configured to provide the patient with a prescription for the digital therapeutic agent as a specific behavioral task that the patient can perform based on the interaction of biochemical factors and the patient's behavior for maintaining, optimizing, and enhancing the immune system of the subject. For example, all types of biochemical factors that can be triggered to maintain, optimize, and enhance the immune system of the subject can be considered.

[0101] The digital task generator may generate a digital task based on input from a doctor. In this case, the digital task generator may generate a digital task based on information collected when a doctor diagnoses a patient. The digital task generator may also generate a digital task based on information received from a patient. For example, the information received from a patient may include a patient's baseline factors, medical information, and digital therapeutics literacy. In this case, the baseline factors may include the patient's activity level, heart rate, sleep, diet (nutrition and calories), etc. The medical information may include the patient's electronic medical record (EMR), family history, genetic vulnerability, genetic susceptibility, etc. The digital therapeutics literacy may include the patient's accessibility and accommodation posture to digital therapeutic tasks and devices, etc.

[0102] The digital challenge generator generates and provides to the patient digital challenges specifically designed to enable the patient to achieve a therapeutic benefit, for example, the digital challenge generator can generate specific digital challenges for each of the digital therapeutic modules, such as the exercise and VNS modules described herein.

[0103] The result analysis unit can collect the patient's behavioral compliance or participation in a predetermined period of time and report the patient's behavioral compliance or participation to an external system. Thus, a doctor can continue to monitor the progress of the digital task through the application, even if the patient does not visit the hospital in person.

[0104] The database can store information regarding maintaining, optimizing, or enhancing the immune system of a subject, such as a treatment hypothesis for maintaining, optimizing, or enhancing the immune system of a subject, digital information provided to a user, user performance result data, etc. The database is included in a digital device for processing maintaining, optimizing, or enhancing the immune system of a subject. However, the database can be provided to an external server.

[0105] A session can include any number of digital therapeutic modules (e.g., a VNS module and / or a motor module). In some embodiments, a session can include two or more digital therapeutic modules. In some embodiments, a session can include 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 20 or more, or 25 or more digital therapeutic modules. A session can include any number of digital therapeutic modules, and the digital therapeutic modules can be independently selected from the vagus nerve stimulation module and the motor module. A session can be repeated as often or infrequently as needed. In some embodiments, a session can be repeated 5 times a day, 4 times a day, 3 times a day, 2 times a day, daily, every 2 days, every 3 days, every 4 days, every 5 days, every 6 days, every 7 days, every 2 weeks, every 3 weeks, or every 4 weeks.

[0106] FIG. 21 illustrates a flow chart illustrating a system for managing maintaining, optimizing, or enhancing a subject's immune system, the system including a digital device configured to run a digital application (e.g., application or "app") for managing maintaining, optimizing, or enhancing a subject's immune system, a healthcare provider portal (e.g., doctor's web), and an administrative portal (e.g., administrator's web), where the administrator's portal allows an administrator to issue physician accounts, review physician information, and review de-identified patient information. Where the healthcare provider portal allows a healthcare provider (e.g., doctor) to issue patient accounts and review patient information (e.g., age, prescription information, and status of completing one or more digital therapeutic modules or sessions). Where the digital application allows patient access to complete one or more digital therapeutic modules or sessions.

[0107] FIG. 26a illustrates a flow chart illustrating an execution flow for login verification during a splash process at the start of a digital application. Similarly, FIG. 26b also illustrates a flow chart illustrating an execution flow for prescription verification during a splash process at the start of a digital application. The prescription verification process can include, for example, determining if a treatment period has expired, determining if the subject has recently performed a VNS module (e.g., within the last hour), and determining if the subject's session has been completed for that date based on the prescription (e.g., the subject is compliant with the prescription). In such an example, the digital device can notify the subject that no sessions are available for completion.

[0108] In some embodiments, the healthcare provider portal provides one or more options to the healthcare provider, and the one or more options provided to the healthcare provider are selected from the group consisting of adding or removing a subject, viewing or editing personal information about the subject, viewing compliance information for the subject, reviewing the subject's results for one or more at least partially completed digital therapeutic modules, prescribing one or more digital therapeutic modules to the subject, changing a prescription for one or more digital therapeutic modules, and communicating with the subject. In some embodiments, the one or more options include viewing or editing personal information about the subject, and the personal information includes one or more selected from the group consisting of a subject identification number, a subject's name, a subject's date of birth, a subject's email, a subject's guardian email, a subject's contact phone number, the subject's prescription, and one or more notes created by the healthcare provider for the subject. In some embodiments, the personal information includes a prescription for the subject, and the prescription for the subject includes one or more selected from the group consisting of a prescription identification number, a prescription type, a start date, a duration, a completion date, a number of digital therapeutic modules scheduled or prescribed to be performed by the subject, and a number of digital therapeutic modules scheduled or prescribed to be performed by the subject per day. In some embodiments, the one or more options include viewing compliance information, the subject's compliance information including one or more of a number of scheduled or prescribed digital therapeutic modules completed by the subject, and a calendar identifying one or more dates on which the subject completed, partially completed, or did not complete the one or more scheduled or prescribed digital therapeutic modules. In some embodiments, the one or more options include a subject outcome display, the subject's outcomes for the at least partially completed one or more digital therapeutic modules include one or more selected from the group consisting of: a time the subject started the scheduled or prescribed digital therapeutic module, a time the subject finished the scheduled or prescribed digital therapeutic module, and an indicator of whether the scheduled or prescribed digital therapeutic module was fully or partially completed.

[0109] The healthcare provider portal dashboard displays the number of all patients currently associated with the physician account. A graph can be used to show the number of patients who have opened the digital application for the patient per day for the last 90 days. The number of ongoing patients is also viewed. A graph can be used to show the number of patients who have completed a daily session for the last 90 days. The healthcare provider portal Patients tab includes (1) Patient ID (a unique identification number temporarily given to each patient when they are added to the list), (2) Patient Name, (3) a search bar to search by ID, name, email, notes, etc., and (4) an Add New Patient button to add a new patient. The healthcare provider portal Patients tab displays (1) detailed patient information, (2) a button to edit the patient information, (3) prescription information, (4) a button to add a new prescription, (5) progress status for each different prescription, and (6) a button or link to forward the email to the patient. The healthcare provider portal Patients tab for adding a new patient displays (1) a button to add a new patient, and (3) an error message that is displayed when the required patient information is not provided. The healthcare provider portal patient tab for editing information for an existing patient includes (1) a button or link to reset password, (2) a button to delete the presented patient, and (3) a button to save changes. FIG. 37 illustrates the healthcare provider portal patient tab displaying detailed prescription information for a presented patient. As shown, (1) is a button to edit prescription information, (2) displays the duration of sessions the patient or subject has attended, and (3) provides an overview of treatment progress. Seven days are represented by a line or row of seven squares. Twelve weeks can be presented, six of each. Different colors can be used to differentiate session status (e.g., gray if the session has not started, red for sessions not attended, yellow for sessions attended partially, and green for sessions attended fully).In some embodiments, the administration portal provides one or more options to an administrator, and the one or more options provided to the system administrator are selected from the group consisting of adding or removing a healthcare provider, viewing or editing personal information of a healthcare provider, viewing or editing de-identified information of a subject, viewing adherence information for a subject, viewing subject results for one or more at least partially completed digital therapeutic modules, and communicating with a healthcare provider. In some embodiments, the one or more options include viewing or editing personal information, and the personal information of a healthcare provider includes one or more selected from the group consisting of an identification number for a healthcare provider, a name of a healthcare provider, an email of a healthcare provider, and a contact number of a healthcare provider. In some embodiments, the one or more options include viewing or editing de-identified information of a subject, and the de-identified information of a subject includes one or more selected from the group consisting of an identification number for a subject and a healthcare provider for the subject. In some embodiments, the one or more options include viewing or editing adherence information for a subject, and the subject's adherence information includes one or more of a number of scheduled or prescribed digital therapeutic modules completed by the subject, and a calendar identifying one or more dates on which the subject completed, partially completed, or did not complete one or more scheduled or prescribed digital therapeutic modules. In some embodiments, the one or more options include an indication of a subject's outcome for one or more at least partially completed digital therapeutic modules, the subject's outcome including one or more selected from the group consisting of: a time when the subject started a scheduled or prescribed digital therapeutic module, a time when the subject finished a scheduled or prescribed digital therapeutic module, and an indicator of whether the scheduled or prescribed digital therapeutic module was fully or partially completed.

[0110] The Administration Portal dashboard shows (1) the number of doctors. Graphs can be used to show the number of doctors who visited the digital application in a day for the last 90 days, and (2) the number of all patients associated with any doctor account. Graphs can be used to show the number of patients who opened the digital application for a patient in a day for the last 90 days. The number of ongoing patients is also seen. Graphs can be used to show the number of patients who completed a day session in the last 90 days. The Administration Portal Doctors tab displays a list of doctors. The Doctors tab further displays (1) a search bar to search for various doctors by name, email, etc., (2) a button to add a new doctor, (3) doctor ID, (4) a button to view detailed doctor information, and (5) inactive doctor accounts. The Administration Portal Doctors tab displays a list of patients under the care of the presented doctor, with patient identifying information redacted(*). The Doctor tab further displays the Doctor's account information, (2) a button to edit the Doctor's account information, (3) a list of patients under the Doctor's care, (4) a list of patient ID numbers, (5) a link or button to forward the Doctor's registration email, (6) a notification that the Doctor's account has been deactivated that appears only for deactivated accounts, and (7 and 8) deleted or de-identified patient information.

[0111] With regard to certain embodiments of the present disclosure, only patients prescribed by a healthcare provider can use the digital application. The patient can visit the doctor to receive the prescription. The doctor can provide the prescription on an n-weekly basis, where "n" can be any number. The patient's application data can be accessed through the healthcare provider or management portal. In certain embodiments, the patient can exercise 2-3 times per week and perform VNS for 10 minutes daily. In certain embodiments, a time gap of 5-6 hours is required between exercise and VNS. In general, exercise can mean a moderate level of aerobic exercise. A schedule for exercise can be suggested based on heart rate data measured during previous exercise through a wearable device (smart watch). In certain embodiments, a smart watch can be used that automatically links with the health kit of the presented platform (iOS, Android). Push notifications can be used to remind the patient of their schedule for exercising and performing VNS.

[0112] Although the features and components are described above in specific combinations, one skilled in the art can understand that each feature or component may be used alone or in any combination with other features and components. Also, the methods described herein may be implemented in a computer program, software, or firmware embodied in a computer-readable medium for execution by a computer or processor. Examples of computer-readable media include electronic signals (transmitted through wired or wireless connections) and computer-readable storage media. Examples of computer-readable storage media include, but are not limited to, read-only memory (ROM), random-access memory (RAM), registers, cache memory, semiconductor memory devices, magnetic media, such as internal hard disks and removable disks, magneto-optical media, and optical media, such as CD-ROM disks and digital versatile disks (DVDs). Processors in conjunction with software may be used to implement a radio frequency transceiver for use in a WTRU, UE, terminal, base station, RNC, or any host computer.

[0113] In one aspect, the present disclosure also relates to a non-transitory computer readable medium having stored thereon software instructions for maintaining, optimizing or enhancing the immune system of a subject in need thereof, the software instructions, when executed by a processor, to cause the processor to: display, via an electronic device, to the subject, a first exercise module and / or a first vagus nerve stimulation module, each of the first modules including a challenge for the subject to follow; sense, via a sensor of the electronic device, whether the subject follows the challenge of the first module; transmit, via the electronic device, compliance information to a server based on the compliance; receive from the server one or more second challenges based on the compliance information; and display, to the subject, a second exercise module and / or a second vagus nerve stimulation module, the second module including the one or more second challenges. In some embodiments, the digital application for maintaining, optimizing or enhancing the immune system instructs a processor of the digital device to perform operations including generating a digital therapeutic module for maintaining, optimizing or enhancing the immune system based on age and / or target heart rate.

[0114] In one aspect, the present disclosure relates to the following embodiments:

[0115] The present disclosure relates to a method for use with a device for providing antiviral digital immunity (ADI), the method comprising generating an antiviral digital vaccine (ADV) including one or more digital challenges that induce at least one of natural killer (NK) cell mobilization, T cell boosting, or vagus nerve stimulation (VNS) in a user's immune system, and providing the one or more digital challenges via the device.

[0116] The one or more digital tasks related to NK cell recruitment can include vigorous exercise, moderate exercise, or light exercise. The method can further include determining a level of vigorous exercise, where moderate or light exercise is determined based on heart rate (HR), repetition maximum (RM), metabolic equivalents (METs), maximum oxygen uptake (VO 2max ) / Oxygen Reserve Uptake (VO2R) or Rate of Perceived Exertion (RPE).

[0117] In some embodiments, the one or more digital challenges for T cell boosting include aerobic exercise or acute exercise. The method includes measuring HR, RM, METs, VO 2max The method may further include determining a level of aerobic or acute exercise based on at least one of the following: / VO2R, or RPE.

[0118] In some embodiments, the one or more digital tasks for the VNS include at least one of a visual, auditory, tactile, gustatory, or olfactory stimulus that increases sIgA secretion.

[0119] In some embodiments, the method may further include receiving a result of the user's performance on the one or more digital challenges, and generating a second ADV based on the result, the second ADV including one or more digital challenges that induce at least one of NK cell recruitment, T cell boosting, or VNS in the user's immune system. In additional embodiments, the user's performance on the one or more digital challenges is repeated a predetermined number of times.

[0120] The present disclosure relates to an apparatus for providing antiviral digital immunity (ADI), the apparatus generating an antiviral digital vaccine (ADV) including one or more digital challenges to induce at least one of natural killer (NK) cell recruitment, T cell boosting, or vagus nerve stimulation (VNS) to a user's immune system; and a processor configured to provide the one or more digital challenges through the apparatus. In some embodiments, the one or more digital challenges for NK cell recruitment include vigorous exercise, moderate exercise, and light exercise. In additional embodiments, the processor is configured to generate a digital challenge that includes heart rate (HR), repetition rate (RM), metabolic equivalents (METs), maximum oxygen uptake (VO 2max In a further embodiment, the one or more digital challenges related to T cell boosting include aerobic exercise or acute exercise. In yet a further embodiment, the processor is further configured to determine a level of vigorous, moderate or light exercise based on at least one of HR, RM, METs, VO2R, or RPE. 2max The processor is further configured to determine a level of aerobic or acute exercise based on at least one of the following: / VO2R, or RPE. In yet further embodiments, the one or more digital tasks for the VNS include at least one of visual, auditory, tactile, gustatory, or olfactory stimuli that increase sIgA secretion. In some embodiments, the processor is further configured to receive a result of the user's performance on the one or more digital tasks, and generate a second ADV including one or more digital tasks that induce at least one of NK cell recruitment, T cell boosting, or VNS in the user's immune system based on the result. In some embodiments, the user's performance on the one or more digital tasks is repeated a predetermined number of times.

[0121] The present disclosure relates to a method of providing antiviral digital immunity (ADI) to a subject using an antiviral digital vaccine (ADV), the method comprising administering, by the subject, the ADV comprising one or more digital challenges that trigger the subject's immune system to at least one of natural killer (NK) cell mobilization, T cell boosting, or vagus nerve stimulation (VNS). In some embodiments, the one or more digital challenges related to NK cell mobilization comprise vigorous exercise, moderate exercise, or light exercise. In additional embodiments, the one or more digital challenges related to T cell boosting comprise aerobic exercise or acute exercise. In additional embodiments, the one or more digital challenges related to VNS comprise at least one of visual, auditory, tactile, gustatory, or olfactory stimuli that increase sIgA secretion.

[0122] example Example 1: Clinical trial to evaluate the efficacy, safety and feasibility of the methods and devices of the present disclosure in healthy adults A single-center, randomized, open-label, no-treatment controlled, medical device clinical trial was conducted to evaluate the efficacy, stability, and feasibility in healthy adults aged 19-45 years.

[0123] The inclusion criteria were: 1) healthy adult males and females aged 19-45 years; 2) individuals who received influenza vaccination in the last year; 3) individuals who are planning to receive influenza vaccination; 4) individuals who are deemed suitable as subjects based on the investigator's judgment through screening tests (clinical findings, medical history, vital signs, body mass index, physical examination, laboratory tests); 5) individuals who do not exercise regularly: individuals who are in a low-intensity activity state (IPAQ2 or 3, or 600 or 700 or 800 or 900 or 1000 or 1500 or 2000 or 3000 or 1000 or 2000 or 3 ... MET-min / week (not corresponding to physical activity less than MET-min / week); 6) if female of childbearing age, if human, who has agreed to avoid pregnancy or use adequate contraception during the clinical trial period; if male, if human, who has agreed to use adequate contraception during the clinical trial period; 7) if human understands and is able to participate in such clinical trial in good faith and agrees to abide by its restrictions; 8) if human agrees to visit for follow-up measures and blood sampling during the study period; 9) if human voluntarily consented to participate in this clinical trial and if the subject voluntarily signed a written consent form; and 10) if human has a smartphone and is able to use the application independently using the smartphone.

[0124] Exclusion criteria were: individuals with a positive test result for a communicable disease (HIV, HBV, HCV), individuals with uncontrolled diabetes (HbA1c ≥ 6.5% or fasting (≥ 8 h) plasma glucose ≥ 126 mg / dL), individuals with a history of tumors, and individuals with a history of autoimmune disease. Exclusion criteria further include: individuals with neurological, cardiovascular, respiratory, hepatic or renal disease (excluding controlled hypertension (systolic / diastolic blood pressure less than 140 / 90 mmHg)); individuals with behavioral, cognitive or psychiatric disorders that, as determined by the investigator, would affect their understanding and compliance with the clinical trial protocol; individuals with a history of acute infectious disease; individuals with a fever of more than 37.5°C within one month prior to screening; individuals who, prior to screening, use immunosuppressants, immunomodulators, immunoglobulins, blood-derived products, or other drugs that may affect immunity, as determined by the investigator as follows: for example, individuals who have received or will receive immunosuppressants during the two months prior to screening, individuals who have received immunomodulators within six months prior to screening, and individuals who have received immunoglobulins or blood-derived products within three months prior to screening. Further exclusion criteria included: individuals who had received a live vaccine within 28 days prior to screening, individuals who had received an inactivated vaccine within 14 days prior to screening, individuals taking medications not approved by the investigator, individuals with a history of alcohol or drug abuse that would affect participation in the clinical trial, individuals who currently smoke, pregnant and breastfeeding women, individuals who had applied / administered a medical device / medication for another clinical trial within 6 months prior to screening or planning and individuals who had applied / administered a medical device / medication during the study period, and individuals who the investigator deemed unsuitable for participation in the clinical trial.

[0125] The overall clinical trial period was 12 months after approval of the clinical trial protocol by each institution's IRB (however, the clinical trial period was modified by enrollment status). The clinical trial period for each subject was approximately 29 weeks. There were two groups for the study: the test group was screened for 4 weeks, the medical device was treated for 13 weeks (including vaccination) based on the completion of the medical device, and followed up within 12 weeks; and the control group was screened for 4 weeks, the medical device was not treated for 13 weeks (including vaccination) based on the completion of the medical device (maintaining the same daily life as before clinical participation), and followed up for 12 weeks.

[0126] Given exercise feedback, changes in the first set target heart rate include: Easy > +3 bpm; Medium > 0 bpm; Hard > -3 bpm. A weekly benchmark exercise record is used to calculate and update the target heart rate as follows (the target heart rate is within the heart rate range between the minimum and maximum values):

[0127] Recording decreased by >+3bpm for 10 seconds or more Recording 0~10 seconds decrease / increase >0bpm Recording increases >-3bpm for 10 seconds or more

[0128] The schedule for the patient was provided to exercise (including both moderate and benchmark exercise) two or three times per week. Considering the total duration of the prescription (e.g., 5 weeks) for odd weeks (e.g., 1, 3, 5 weeks), moderate exercise was scheduled on days 2 and 4 (twice a week), moderate exercise was scheduled on days 1 and 3, and benchmark exercise was scheduled on day 6 (three times a week) for even weeks (e.g., 2, 4 weeks). The patient can change the designed exercise schedule. Only the days on which the patient exercised can be changed (the total number of exercises designed each week cannot be changed). The start date of the prescription is counted as the first day of the week.

[0129] Here, the benchmark exercise aims to identify changes in the patient's stamina by having the patient repeatably perform the same set of exercises once every two weeks. All types of exercise performed during this time are referred to as the benchmark exercise. The benchmark exercise was scheduled on the last day of each week, but was changed at the patient's discretion. Based on the weekly benchmark exercise time record, the new target heart rate was calculated in the following manner:

[0130] Recording decreases to 10 seconds or more > +3bpm Recording decreases / increases from 0-10 seconds to >0 bpm Recording increases >3bpm for 10 seconds or more *10 seconds and 3 BPM were used arbitrarily.

[0131] The clinical trial was designed as a single-institution, open, controlled and investigator-initiated medical device clinical trial to evaluate the efficacy, safety and feasibility of an exemplary digital application on health. The test group then continued to use the medical device for 12 weeks of clinical trials, while the control group maintained their daily activities. The two groups visited the institution at 1 week (Visit 3), 5 weeks (Visit 4), and 13 weeks (Visit 5) from the baseline time point for laboratory tests (including immune indicator tests) and quality of life questionnaires and safety assessments (including influenza symptom identification).

[0132] During the clinical trial, drugs that may have a clinically significant effect on the immune system were prohibited: immunosuppressants, immunomodulators, immunoglobulins, blood-derived products or other drugs that may affect immunity, all vaccines except influenza vaccines, and other drugs not approved by the investigators.

[0133] Changes in NK cell counts for innate immunity assessment were compared to baseline (primary efficacy endpoint) at weeks 1 (V3), 5 (V4), and 13 (V5). Secondary efficacy endpoints included changes from baseline to weeks 1, 5, and 13 in the following indicators: CD4+T cells, CD8+T cells B cells Pro-inflammatory cytokines (IL-6, TNF-a and IL-1b), anti-inflammatory cytokines (IL-10), IFN-γ

[0134] Primary efficacy endpoint: After applying the clinical trial, technical statistics (mean, standard deviation, median, minimum and maximum) for NK cells at 5 weeks and the change compared to baseline were presented by each group, and paired samples t-test or Wilcoxon signed rank test were used to identify changes in each treatment group. Analysis of covariance was performed using corrected baseline values ​​to test for differences between groups.

[0135] Secondary efficacy endpoints: NK cell changes for innate immunity evaluation at 1 week, 13 weeks and 25 weeks compared to baseline: After application of the medical device for the clinical trial, technical statistics (mean, standard deviation, median, minimum, maximum) for each NK cell and the changes at each time point compared to baseline at 1 week, 13 weeks and 25 weeks were presented by group. To test for differences between groups, analysis of covariance was performed using the corrected baseline values. Changes by immune indicators* at 1 week, 5 weeks, 13 weeks and 25 weeks compared to baseline: For each indicator, technical statistics (mean, standard deviation, median, minimum, maximum) for results at 1 week, 5 weeks, 13 weeks and 25 weeks after application of the medical device for the clinical trial and the changes at each time point compared to baseline were presented by group. To test for differences between groups, analysis of covariance was performed using the corrected baseline values. *CD4+ T cells, CD8+ T cells, B cells, proinflammatory cytokines (IL-6, TFT-α and IL-1b), anti-inflammatory cytokines (IL-10), IFN-γ. Antibody production after influenza vaccination: The percentage and frequency of subjects who produced antibodies after influenza vaccination at 5, 13 and 25 weeks were presented, and the percentage of antibodies produced during the clinical trial was presented by group. Chi-square test or Fisher's exact test was used to test for differences between groups. Upper respiratory tract inflammation symptoms onset and severity: The frequency and rate of upper respiratory tract inflammation symptoms at 1, 5, 13 and 25 weeks were presented, and the onset and severity of symptoms were presented by group. Chi-square test or Fisher's exact test was used to test for differences between groups. Adherence: Technical statistics (mean, standard deviation, median, minimum and maximum) for the adaptation of the study groups were presented. Quality of life questionnaire at 1, 5, 13 and 25 weeks compared to baseline (SF-36): After application of the clinical trial medical device, quality of life (SF-36) scores at 1, 5, 13 and 25 weeks and technical statistics for the change at each time point relative to baseline (mean, standard deviation, median, minimum, maximum) were presented for each group.To test for differences between groups, analysis of covariance was performed using corrected baseline values.

[0136] During the clinical trial, drugs that may have clinically significant effects on the immune system were prohibited: immunosuppressants, immunomodulators, immunoglobulins, blood-derived products or other drugs that may affect immunity, all vaccines except influenza vaccines, and other drugs not approved by the investigators.

[0137] The following scenario requirements were used to test compliance rates:

[0138] Warm-up: Insert "skip" button Warm-up: Change base duration from 5 minutes to 3 minutes. Appropriate external exercise: Added duration indicator (20 minutes) Benchmark exercises: adding more exercise options (increasing compliance rate) Internal activity: Heart rate display during internal activity Activity measurement: Set a time range (5 minutes) to keep activity records if the app is suddenly closed Today's Mood: Added "undo" button Feedback function: Automatic notification transfer if the app is not used for 72 hours Feedback function: Success rate display Feedback feature: Automatic schedule notification insertion: D-7, D-1, D-day pop-up messages are required. Feedback function: Insert a farewell scene or a pop-up window when the last activity is completed. Feedback function: Schedule progress display

[0139] Figure 40 illustrates the adherence rates: 2 out of 21 in the control group and 1 out of 21 in the experimental group dropout, where over 95% of patients (20 out of 21) completed all schedules in the app over the 3-month period, and over 95% of patients completed 75.8% of the program over the 3-month period.

[0140] Example 2: Mobile application details The operating system includes a patient mobile application (hereinafter, "app"), a doctor's web portal, and a server that connects the two channels.

[0141] To use the application, the physician first logs into the doctor web portal, creates an account for the patient to be prescribed through the doctor web portal, enters the patient information, and prescribes the use of the app. The app is provided to the patient in the form of a mobile app, and the software needs to be downloaded to be prescribed and sent by the doctor, and the patient can log into the app with the patient account and password provided for execution, and receives activities through the app for at least 10 minutes and up to 30 minutes (records of all activities performed by the patient are sent to the doctor web portal, and data transmitted to the server is backed up once a day for loss prevention and restoration functions). The patient app is divided into two sessions: after wearing the wearable device, exercise and immune strengthening activities are performed. After deep breathing, immune strengthening activities are performed daily for a total of 5 minutes by selecting two activities out of five activities, for a total of 10 minutes. Each schedule is adjusted by the patient, and all activities are suspended or stopped in the middle.

[0142] In detail, the patient first accessed the app with his / her login account information, and after the first connection, the app was executed without the need to enter the account information again. Next, the patient pressed the start button on the screen to perform the session. If the specific amount of time was not met at the end of the exercise, it was recorded as not being done. The vagus nerve stimulation activity was performed as two different activities, and each activity must be performed consecutively to be recorded as completed. The patient can stop using the app during or between sessions at any time or when it is inconvenient, and can also encourage themselves to progress in the session by setting up push notifications for each session progress. In summary, the patient logged in, checked the health status of the day on the first screen, selected one session between exercise and immune-boosting activity, performed the appropriate activity for each session, and the activity of each session was recorded. If the specific time (e.g., 20 minutes for exercise and 10 minutes for vagus nerve stimulation) was not met, the activity was recorded as not being completed, and the daily record was collected and checked separately. The first activity was exercise, and the second activity was vagus nerve stimulation activity. The exercises were performed two to three times a week, the schedule could be freely set, and each exercise took 20 minutes. The vagus nerve stimulation activity was performed once a day and took 10 minutes.

[0143] [Table 2]

[0144] In the test trial, exercise sessions were conducted 2 to 3 times a week for a total of 30 minutes, including a 5-minute warm-up before starting, 20 minutes of exercise, and 5 minutes of warm-up (a target heart rate was suggested before exercise). During exercise, a wearable device, Mi Smart Band (Xiaomi, China), was worn on the wrist to measure heart rate and send it to the patient app. The exercise could be stopped by pressing the "Stop Exercise" button. After the exercise, a subjective evaluation of the exercise intensity was performed to adjust the target intensity of the next exercise. The exercise schedule was replaced by a benchmark exercise once every two weeks to see how the patient's physical strength changed. This consisted of a total of nine exercises, and each exercise was performed, the activity time was recorded and compared with the previous record. The target heart rate for the next exercise was adjusted according to the benchmark exercise results (± 3 bpm). Vagus nerve stimulation activities were performed every day, and two activities were performed. The first activity was performed for 5 minutes as deep breathing, and the next activity was performed by selecting one of the five activities. Examples of vagus nerve stimulation activities include the following.

[0145] Take a deep breath → Breathe in and out following the instructions on the screen. White noise listening: Sit in a comfortable position and listen to the natural sounds provided by the app. Hold your breath → Follow the instructions on the screen to hold your breath for 30 seconds, then breathe again. Aroma Meditation: After preparing aromas such as candles and a diffuser, meditate by following the voice guidance in the app. Horror experience → You are presented with a sense of fear through color and are asked to stare at the screen. Submerge your face in cold water → Prepare the cold water as instructed by the app, and submerge your face in the water for 10 seconds, then take a 1 minute 30 second break, and repeat this for 5 minutes.

[0146] Example 3: Pathogenesis Physical activity is measured in metabolic equivalents (METs), where 1 MET is defined as the energy required to sit quietly. Moderate activity corresponds to 3-6 METs, and vigorous activity corresponds to more than 6 METs. Converting such moderate activity into heart rate corresponds to 64-76% of maximum heart rate, and heart rate by age can be estimated by the following mathematical formula (unit: bpm):

[0147] (Maximum heart rate - stable heart rate) x target exercise intensity (%) + stable heart rate.

[0148] The maximum heart rate was calculated to be 220. With reference to the heart rates organized by age group, the app presents the heart rate corresponding to moderate exercise according to the patient's age group and presents a "target heart rate" to reach it. Heart rate was measured in real time using a wearable device Xiaomi Mi Smart Band 4. The patient wore this device on one wrist before exercising, and the device's photoplethysmogram (PPG) heart rate sensor measured the heart rate and transmitted it to the patient app. The PPG heart rate sensor is based on the principle of optical blood flow measurement called PPG. PPG is used to measure changes in the blood volume of capillaries. This is then converted into an electrical signal and the peak value from the measured values ​​is displayed as the heart rate. Exercise was simultaneously measured by subjective assessment. In the app, the patient was asked to evaluate the exercise intensity in three steps after finishing the exercise and to adjust the next target heart rate according to the results (± 3 bpm).

[0149] This is designed to induce an immune system strengthening effect by setting the duration of the exercise at 20 minutes.

[0150] Example 4: Safety report The study subjects were as follows:

[0151] Screening n=53 Randomized n=42 (experimental group: 21, control group: 21) Completed study subjects n=39 (v4 points: 40)

[0152] Experimental group: 20 Control group: 19 (completed v4:20)

[0153] Experimental groups: R031 (dropped out after V3 visit): taking steroids due to rash and tingling sensation caused by wearing a mask; steroids prescribed by a dermatologist do not match the content standard (Methylon Tab 4 mg, Ebastel Tab 10 mg, Stogar Tab 10 mg per tablet per day for 10 days). Control groups: R009 (dropped out after V2 visit): taking hormones (for the treatment of secondary amenorrhea); and R010 (completed V4 visit): receiving hormones (Senselibe Tab 1 T / d). After the completion of V4 visit, both groups had no flu-like symptoms: experimental and control

[0154] [Table 3] *Amenorrhea was discovered prior to enrollment in the clinical trial, but not in the past medical history. After the v2 visit, the hormone prescription was determined by the obstetrician-gynecologist, and the subject was dropped midway through the clinical trial.

[0155] [Table 4] **Knee Pain is an AE-related device.

[0156] The experimental groups included: 1. Period pain (3): V4-V5 3 patients, (pain relief: 2 with EZN6, 1 with Tyrenol), 2. Surgery for uterine fibroids (1): V4-V5, after surgery, taking Feroba, 3. Headache (1): V4-V5: (Carol-f Tab. Naproxen / EZN6, 4. Depression (1): diagnosed with corona-blue, Lexapro, 5. Knee pain (1): 2 days before V3 visit, 2 external activities (exercise) due to application activation malfunction. Pain developed and continued until V3 visit. No medication.

[0157] The control group included: 1. Painful period (1): V4-V5, twice, Tylenol, 2. Irregular period (1): Prescribed hormones and dropped midway through the trial. 3. Amenorrhea (1): Found before enrolling in the trial but not found in past medical history. After the v2 visit, hormone prescription is decided by the obstetrician-gynecologist and the subject is dropped midway through the trial. 4. Hemorrhoids (1): V4-V5, medication for hemorrhoids, 5. Lumbar pain (1): No medication, 6. Ear inflammation: One-time medication with Advil.

[0158] Example 5: Research Summary A single-center, randomized, open-label, no-treatment-controlled, digital device study was conducted to evaluate the efficacy, safety, and feasibility of the app in healthy adults aged 19-50 years. The purpose of this clinical trial is to evaluate the efficacy, safety, and feasibility of the app in healthy adults. The study consisted of two groups, namely, the control group (N=16, visit 5: N=15) and the test group (SAT-008 group: N=16; serve-group: high performance (N=6), low performance (N=10)). From baseline to 13 weeks, the test group used the mobile application device, and the control group did not use the app and maintained the same daily routine as baseline. After baseline, influenza vaccination was provided at 1 week, and blood samples were collected at baseline, 1 week, 5 weeks, and 13 weeks to observe the changes in immune cells in each group and between groups compared to baseline, and to check the changes in influenza antibody production rate and titer between groups compared to the vaccination date (1 week). The study was 12 months from the date of IRB approval.

[0159] The investigator (physician) entered the study subject's information through a physician's website and prescribed the mobile application for use, and the subject or agent who received the prescription was issued login information to access the app. Research subjects installed the app on their own smartphone (or the smartphone paid for by the study), logged in, and ran it.

[0160] The app consisted of exercise activities and immune-boosting activities, with the exercise activities being performed two to three times a week and the immune-boosting activities being performed daily. Subjects began by selecting the exercise and immune-boosting activities on the application screen. Before starting both activities, the app asked the subject's physical condition. If the subject responded that they were not healthy due to fever or body pain, the activity selection button on the application was deactivated, thereby preventing them from performing the activities that day.

[0161] Exercise activities were performed for 30 minutes (including warm-up and cool-down exercises) two to three times a week. During exercise, the study subjects wore a wearable device (smart watch: Mi Smart Band 5.0) to transmit the subjects' exercise status information to the application. If the subjects felt difficulty during exercise, they stopped exercising and resumed it at any time. If the exercise time measured after the subjects pressed the exercise end button was short, the exercise activity was not recorded.

[0162] To check the changes in the subjects' physical fitness, a benchmark exercise was conducted once every two weeks. The benchmark exercise consisted of three sets of three exercises, and the duration and frequency of the exercises were measured. This was done every other week to check for changes in duration and frequency.

[0163] The immune-boosting activities consisted of five static activities, two of which were performed for 10 minutes each day, with each activity lasting 5 minutes and the two activities performed consecutively so that the activities were recorded as completed.

[0164] Any activity can be stopped at any time even if it is in progress and can be restarted from the interrupted point only on the same day. It is important that subjects are consistent with their schedule and perform activities through the app, and the application can set up push notifications to encourage continued activity schedules.

[0165] Activity data was transmitted in real time to the investigator, who had access to DoctorWeb to check the activity details of the research subjects.

[0166] This study was designed as a single-center, open-label, controlled and investigator-initiated study to evaluate the efficacy, safety and feasibility of a research digital device in the form of a mobile application in healthy adults receiving influenza vaccination. At the screening visit (Visit 1), subjects voluntarily provided written consent to participate in the study and then underwent screening procedures. If they met the inclusion criteria and did not meet the exclusion criteria, study subjects were randomly assigned 1:1 to the experimental group (using the research digital device) and the control group (maintaining daily activities) (Visit 2). For the experimental group, the research digital device was used 7 times a week. For the control group, daily activities were maintained as they were before participating in the study and no intervention was performed.

[0167] The following medical histories were collected regardless of the time period: uncontrolled diabetes (HbA1c ≥ 6.5% or fasting (≥ 8 h) plasma glucose ≥ 126 mg / dL); tumor; autoimmune disease; neurological disease; cardiovascular disease; respiratory disease; liver or kidney disease; acute infectious disease. The following medical histories were investigated according to the relevant time period: fever above 38°C (within 4 weeks before screening). Both the test and control groups visited the implementation site 1 week later (Visit 3) and received influenza vaccination. After that, the test group continued to use the research digital device for 12 weeks, and the control group maintained their daily activities. Both groups visited the implementation site 5 weeks (Visit 4) and 13 weeks (Visit 5) from the baseline time and were evaluated for laboratory tests and immunological indicators, quality of life questionnaires, and safety (including identification of influenza symptoms).

[0168] The main inclusion criteria were: healthy adult males and females aged 19-45 years, individuals who received influenza vaccination in the last year, individuals who are scheduled to receive influenza vaccination, individuals who are deemed suitable as subjects based on the investigator's judgment through screening tests (clinical findings, medical history, vital signs, body mass index, physical examination, laboratory tests), individuals who do not exercise regularly: individuals who are under low intensity activity (IPAQ 2 or 3, or physical activity less than 600 MET-min / week) as a result of physical activity assessment using the International Physical Activity Questionnaires (IPAQ). For women of childbearing age, individuals who agree to avoid pregnancy or use appropriate contraception during the clinical trial; for men, individuals who agree to use appropriate contraception during the clinical trial. Individuals who understand and are able to participate in such clinical trials in good faith and agree to abide by the restrictions. Individuals who agree to visit for follow-up measures and blood sampling during the study period. Individuals who voluntarily agree to participate in this research and sign a written consent form. Individuals who are able to use the application using a smartphone.

[0169] Major inclusion and exclusion criteria included: individuals with some medical history, e.g., current infectious disease (HIV, HBV, HCV) positive test results, individuals with uncontrolled diabetes (HbA1c 6.5% or higher or fasting (8+ hours) plasma glucose 126 mg / dL or higher), individuals with a history of tumors, individuals with a history of autoimmune disease.

[0170] Major inclusion and exclusion criteria further include: persons with neurological, cardiovascular, respiratory, hepatic or renal disease (excluding controlled hypertension (systolic / diastolic blood pressure less than 140 / 90 mmHg)); persons with behavioral, cognitive or psychiatric disorders that, as determined by the investigator, would affect their understanding and compliance with the clinical trial protocol; persons with a history of acute infectious disease; persons with a fever of more than 37.5°C within 4 weeks prior to screening; persons who, prior to screening, use other medications such as immunosuppressants, immunomodulators, immunoglobulins, blood-derived products, or other medications that may affect immunity, as determined by the investigator as follows:

[0171] Individuals who have received immunosuppressive drugs within 60 days prior to screening or who will be receiving such drugs during the clinical trial; People who had received immunomodulatory drugs within 6 months prior to screening Individuals who received immune globulin or blood-derived products within 3 months prior to screening

[0172] In addition, the main inclusion and exclusion criteria were: individuals who, in the investigator's judgment, had received a live vaccine within 28 days prior to screening; individuals who had received a killed vaccine within 14 days prior to screening; individuals taking medications not approved by the investigator; individuals with a history of alcohol or drug abuse that would affect participation in the clinical trial; individuals who currently smoke; pregnant and breastfeeding women; individuals who had applied / administered a medical device / medication for another clinical trial within 6 months prior to screening or planning and who applied / administered a medical device / medication during the study period; and individuals who the investigator judged to be unsuitable to participate in the clinical trial.

[0173] The primary efficacy endpoint included change in NK cell response to innate immunity assessment at week 5 compared to baseline, and secondary efficacy endpoints included: Changes in NK cell numbers and activity for innate immunity assessment at 1 and 13 weeks compared to baseline.

[0174] Changes in the following indicators at weeks 1, 5, and 13 compared to baseline CD4+ T cells, CD8+ T cells: B cells Pro-inflammatory cytokines (IL-6, TFT-α and IL-1b), anti-inflammatory cytokines (IL 10), IFN-γ. Changes in antibody production rates and antibody titers after influenza vaccination in blood samples collected at weeks 5 and 13 compared with the day of vaccination. Influenza-like symptoms (fever >37.8°C and cough or sore throat) or confirmed influenza on the day of vaccination, Visit 4, or Visit 5. Adaptability. Quality of Life Questionnaire (SF-36) at 1, 5, 13, and 25 weeks compared with baseline. Inspection / visit schedule.

[0175] [Table 5] JPEG2024541932000007.jpg245170JPEG2024541932000008.jpg88170

[0176] The screening visit (Visit 1) and the baseline visit (Visit 2) could occur on the same day. If performed on the same day, duplicate tests would be performed only once. The baseline test would be performed before the use of the research digital device. From then on, the date of visit to the realization site would be based on the baseline visit (Visit 2). In case of dropout or early termination, the same tests and evaluations as at the termination visit should be performed. All procedures related to the study were performed after obtaining written consent. Demographic information questionnaire: Demographic information (age, sex, etc.) would be surveyed by questionnaire. Vital signs (blood pressure, respiratory rate, pulse, temperature) were measured at each visit. Physical activity was assessed using the shortened Korean version of the International Physical Activity Questionnaire. If there was a test result measured within 4 weeks prior to screening, this test result was used. However, if there was a clinically significant abnormal result according to the investigator's judgment, an additional test was performed at screening. Hematological tests: Hb, Hct, RBC, WBC, differential WBC count, platelet count; blood chemistry tests: Na, K, Cl, P, Ca, creatinine, BUN, uric acid, ALT, AST, ALP, CPK, total bilirubin, amylase, lipase, albumin, total protein, HbA1c, FBG (FPG); urinalysis: pH, specific gravity, nitrite, protein, glucose, ketone bodies, bilirubin, urobilinogen, occult blood, WBC, etc. Immunologic tests included HBsAg, HCV Ab, and HIV Ab. For women of childbearing age, pregnancy testing was performed at visit 1, followed by urine HCG or serum HCG testing. Immune-marker tests included NK cells, CD4+ T cells, CD8+ T cells, proinflammatory cytokines (IL-6, TFT-α, and IL-1b), anti-inflammatory cytokines (IL-10), and IFN-γ. Quality of life was assessed using the SF-36 questionnaire. Research subjects assigned to the study group continued to use the research digital device for 13 weeks from the baseline visit, at the end of which it was automatically deactivated. If the clinic visit and the exercise day overlapped, the exercise was performed after the clinic visit was completed.Symptoms or symptoms that were present before the application of the research digital device / medicine (influenza vaccine) that worsened after the application of the research digital device / medicine were reported as abnormal cases. Abnormal cases related to the influenza vaccine were identified as local and systemic and checked for the presence of influenza-like symptoms. Acute abnormalities such as anaphylaxis were checked 30 minutes after influenza vaccination.

[0177] Technical statistics (mean, standard deviation, median, minimum, maximum) for NK cell results and changes compared to baseline 5 weeks after application of the research digital device were presented by group, and changes within each group were checked with paired t-test or Wilcoxon signed-rank test. Analysis of covariance was performed to test for differences between groups.

[0178] Secondary efficacy endpoints included: 1) change in NK cell count and activity for innate immunity assessment at weeks 1 and 13 compared to baseline, 2) technical statistics (mean, standard deviation, median, minimum, maximum) for NK cells at weeks 1 and 13 after application of the Research Digital Device and the amount of change at each time point compared to baseline were presented for each group. Analysis of covariance was performed using corrected baseline values ​​to test for differences between groups, and 3) immune index at weeks 1, 5, and 13 compared to baseline. *4) For each indicator, technical statistics (mean, standard deviation, median, minimum, maximum) for the results at 1 week, 5 weeks, and 13 weeks after applying the digital device for research and the change at each time point compared to baseline were presented by group. Analysis of covariance was performed using corrected baseline values ​​to test for differences between groups. *CD4+T cells, CD8+T cells, B cells, proinflammatory cytokines (IL-6, TFT-α, and IL-1b), antiinflammatory cytokines (IL-10), IFN-γ.5) Changes in antibody production rate and antibody titers after influenza vaccination, 6) Percentages of influenza antibodies at 1 week (before vaccination on the day of vaccination), 5 weeks, and 13 weeks were presented for each group, and changes within groups were confirmed by paired sample t-test or Wilcoxon signed rank test. Analysis of covariance was performed to test for differences between groups; 7) influenza-like symptoms and confirmation; 8) frequency and percentage of influenza-like symptoms or confirmation of influenza-like symptoms at weeks 1, 5, and 13 were presented. The incidence and severity of each symptom were presented by group and chi-square test or Fisher's exact test were used to test for differences between groups. test) was performed, 9) habituation, 10) technical statistics (mean, standard deviation, median, minimum, maximum) for each section (exercise and immunization activities) and total sessions for the number of completions, discontinuations and non-completions of the study group at 1, 5 and 13 weeks were presented, 11) the quality of life questionnaire at 1, 5 and 13 weeks was compared with baseline (SF-36), 12) technical statistics (mean, standard deviation, median, minimum, maximum) for the scores of each item of the quality of life questionnaire (SF-36) at 1, 5 and 13 weeks after applying the digital device for research and the amount of change at each time point compared to baseline were presented for each group and an analysis of variance was performed to test item-specific differences in the quality of life questionnaire between the groups.

[0179] The incidence, expression rates (%), and number of subjects with expression (occurring after application of the research digital device) for Treatment-Emergent Adverse Events (TEAEs), Adverse Device Effects (ADEs), Serious Adverse Events (SAEs), and Serious Adverse Device Effects (SADEs) are presented. Two-sided 95% confidence intervals for the incidence rates (%) were also presented. Chi-square tests or Fisher's exact tests were performed to test whether there were differences in the occurrence of adverse events between groups.

[0180] Technical statistics (number of study subjects, mean, standard deviation, median, minimum, maximum) for each time point and the amount of change at each time point compared to baseline values ​​for vital sign results were presented. Changes within groups were confirmed with paired samples t-tests or Wilcoxon signed rank tests. Also, two-sample t-tests or Wilcoxon signed rank tests were performed to test differences between groups for changes before and after application of the research digital device. For each item of the physical examination, results showing clinically significant abnormalities (abnormalities / CS) at least once after application of the research digital device were ranked.

[0181] For laboratory test results, continuous variables provide technical statistics (number of subjects, mean, standard deviation, median, minimum, maximum) for each time point and the amount of change at each time point compared to the baseline value. Changes within groups were confirmed with paired samples t-tests or Wilcoxon signed rank tests. Also, to test the differences between groups for changes before and after the application of the research digital device, two-sample t-tests or Wilcoxon signed rank tests were performed. Furthermore, the frequency and percentage of subjects showing clinically significant abnormalities (abnormal / CS) at least once after the application of the research digital device for each of the laboratory tests were presented. If necessary, they were divided into normal or clinically insignificant abnormalities (normal or abnormal / NCS) and clinically significant abnormalities (abnormal / CS) and were also presented in the form of a shift table. McNemar's test for changes within groups was performed to check the differences between visits.

[0182] Figures 46-73 illustrate the results from the clinical study described above. All data analyses were performed based on normalization using baseline V2 (folder change).

[0183] FIG. 52 illustrates the difference in NK cell population between groups (Anova analysis) at each visit time point V3 (1 week), V4 (5 weeks), and V5 (13 weeks). NK cell population was decreased at visit 5 compared to visit 4 in the control group, whereas there was no significant change between visit 4 and visit 5 in high and low performers. Statistical analysis showed that naive CD4 T cells showed significant group effects at V4 and V5 as illustrated in FIG. 53, central CD4 T cells showed significant visit effects as illustrated in FIG. 54, CD4 cells showed significant visit and group effects at V4 as illustrated in FIG. 55, and effect memory CD4 cells showed significant visit-group interactions and visit effects as illustrated in FIG. 56. According to the statistical analysis, naive CD8 T cells showed a significant visit effect in the control group as shown in FIG. 57, central CD8 T cells showed a significant visit effect as shown in FIG. 58, effect CD8 T cells showed a significant visit effect and group effect as shown in FIG. 59, and effect CD8 T cells showed a significant visit group interaction as shown in FIG. 60. FIG. 61 and FIG. 62 illustrate the results of the difference in CD4 Treg (CD25+Foxp3+) cell population between groups at each visit time point V3 (1 week), V4 (5 weeks), and V5 (13 weeks) (t-test, P<0.01). The difference in CD4 Treg cell population was not significantly significant between the control group and the experimental group as shown in FIG. 61. CD4 Treg cells showed a tendency to increase in association with the visit, with a significant increase in population in the high compliance group (t=-4.25, P<0.01) as shown in FIG. 62. Figure 63 illustrates the results of the difference in naive B cell population between the groups at each visit time point V3 (1 week), V4 (5 weeks), and V5 (13 weeks) (t-test, P<0.05). The difference in the population of naive B cells was not significant between the control group and the experimental group. Figure 64 illustrates the results of the difference in memory B cell population between the groups at each visit time point V3 (1 week), V4 (5 weeks), and V5 (13 weeks) (t-test, P<0.05). The difference in the population of memory B cells is significant between the control group and the experimental group.Figure 65 illustrates the results of the difference in plasma B cell population between groups at each visit time point V3 (1 week), V4 (5 weeks), and V5 (13 weeks) (t-test, P<0.05). The difference in plasma B cell population is significant between the control group and the experimental group.

[0184] The antibody titer test results are shown in Figures 66-73. All data analysis was performed based on normalization using baseline V2. ANOVA was used to determine whether there were statistically significant differences between groups.

[0185] Example 6: Additional data 1. FIG. 74 illustrates a graph illustrating the change in neutralizing antibody titers of the control and experimental groups at week 5 (V4) and week 13 (V5) compared to baseline (V3). In an embodiment of the present disclosure, subjects were vaccinated with influenza 4 (H1N1, H3N2, B-Phuket, B-Washington) vaccines, and a treatment effect was observed with the B antigen as a result of the difference in antibody titers against each antigen. Compared to the control group, neutralizing antibody titers increased in the experimental group, especially B-Phuket (Yamagata lineage) at week 4 (Visit 4) and B-Washington (Victoria lineage) at week 12 (Visit 5) when compared to the control group.

[0186] Figure 75a, Figure 75b, and Figure 75c show graphs illustrating the changes in T cells and B cells at 1 week (V3), 5 weeks (V4), and 13 weeks (V5) compared to baseline (V2) for the control and experimental groups. (A) For CD8 T cells, the central CD8 T cells in the control group were significantly decreased at 13 weeks compared to previous time points, while for effector CD8 T cells, this increased at 5 weeks. For effector memory CD8 T cells, a significant interaction effect between treatment effect and time was observed. (B) As a result of CD4 T cell analysis, naive CD4 T cells were observed to be higher in the experimental group than in the control group, especially at 5 weeks. For central CD4 T cells, both groups showed a pattern of decrease over time, especially in the control group at 13 weeks, which was significantly decreased compared to previous time points. Effect CD4 T cells showed a significant increase in the control group at week 5, and effect memory CD4 T cells showed a significant interaction between the effect of treatment and time and showed no significant change in the test group. Meanwhile, a decrease and then further increase in fluctuations was observed in the control group at week 5. (C) For B cells, unlike the control group, a statistically significant increase in memory B cells was observed in the test group compared to V3 compared to V5, and also, unlike the test group, a significant decrease in plasma B cells was observed in V4 and V5 compared to V3 in the control group.

[0187] FIG. 76 illustrates graphs illustrating the change in natural killer (NK) cells for the control group and the experimental group at 1 week (V3), 5 weeks (V4) and 13 weeks (V5) compared to baseline (V2). (A) shows the number of NK cells, and (B) shows the percentage of cells activated after stimulation of NK cells. The activated cell percentage of NK cells is considered to reflect its function, and V4 and V5 were later analyzed in which group changes in activity were observed (C). The control group showed a sustained decrease, while the test group showed a tendency to remain undecreased, and it was confirmed that an interaction between the treatment effect and time was statistically observed in the statistical analysis results. In the case of the test group, it is observed that after using the digital device for research, the number and activity of immune cells increased compared to baseline, and the test group also improved when compared to the control group. Furthermore, in the test group, influenza antibody production rate and titer change increased compared to the control group. These results serve as a basis for evaluating whether the app is effective in improving immune function.

[0188] [Table 6]

[0189] For additional details regarding the above-mentioned clinical trials, see the Appendix. The results demonstrate that the exemplary applications described herein can be used to maintain, optimize or enhance a subject's immune system.

[0190] While the present disclosure has been shown and described with reference to specific exemplary embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present disclosure as defined by the appended claims.

[0191] Embodiment Embodiment 1. A method of maintaining, optimizing or enhancing a subject's immune system includes providing a first exercise module and / or a first vagus nerve stimulation module to the subject by an electronic device, each of the first modules including one or more first tasks for the subject to follow.

[0192] Embodiment 2. In a method according to embodiment 1, the method activates or increases the production of natural killer (NK) cells in the subject.

[0193] Embodiment 3. A method according to embodiment 1 or embodiment 2, wherein the method reduces changes in central T cell numbers in the subject.

[0194] Embodiment 4. A method according to any one of embodiments 1 to 3, wherein the method reduces the change in effector T cell count in the subject.

[0195] Embodiment 5. A method according to any one of embodiments 1 to 4, wherein the method reduces the change in memory T cell numbers in the subject.

[0196] Embodiment 6. A method according to any one of embodiments 1 to 5, wherein the method activates or increases the generation of naive CD4 T cells in the subject.

[0197] Embodiment 7. In the method according to embodiment 6, the naive T cells are activated or expanded within one month of provision.

[0198] Embodiment 8. A method according to any one of embodiments 1 to 7, wherein the method reduces changes in central CD4 T cell counts in a subject.

[0199] Embodiment 9. A method according to any one of embodiments 1 to 8, wherein the method reduces a change in effective CD4 T cell count in a subject.

[0200] Embodiment 10. A method according to any one of embodiments 1 to 9, wherein the method reduces a change in memory CD4 T cell count in the subject.

[0201] Embodiment 11. A method according to any one of embodiments 1 to 10, wherein the method reduces changes in naive CD8 T cell numbers in a subject.

[0202] Embodiment 12. A method according to any one of embodiments 1 to 11, wherein the method reduces changes in central CD8 T cell counts in the subject.

[0203] Embodiment 13. A method according to any one of embodiments 1 to 12, wherein the method reduces the change in effective CD8 T cell count in the subject.

[0204] Embodiment 14. A method according to any one of embodiments 1 to 13, wherein the method reduces the change in memory CD8 T cell numbers in the subject.

[0205] Embodiment 15. A method according to any one of embodiments 1 to 14, wherein the method activates or increases the generation of CD4 Treg cells in the subject.

[0206] Embodiment 16. A method according to any one of embodiments 1 to 15, wherein the method activates naive B cells for maturation in the subject.

[0207] Embodiment 17. A method according to any one of embodiments 1 to 16, wherein the method expands naive B cells in the subject.

[0208] Embodiment 18. A method according to any one of embodiments 1 to 17, wherein the method expands memory B cells in the subject.

[0209] Embodiment 19. A method according to any one of embodiments 1 to 18, wherein the method reduces plasma B cells in the subject.

[0210] Embodiment 20. In a method according to any one of embodiments 1 to 19, the method further includes a step of providing a second motor module and / or a second vagus nerve stimulation module to the subject by the electronic device, each of the second modules including one or more second tasks, and the electronic device (i) includes a sensor for sensing the subject's adherence to a first task of the first module, (ii) transmits adherence information to a server based on the adherence, and (iii) receives one or more second tasks from the server based on the adherence information.

[0211] Embodiment 21. In the method according to any one of embodiments 1 to 20, the first motor module and the first vagus nerve stimulation module are provided with a delay time of at least 3 hours.

[0212] Embodiment 22. In the method according to any one of embodiments 1 to 21, a first exercise module is provided, the exercise module including one or more first tasks for stimulating the subject's sympathetic nervous system.

[0213] Embodiment 23. In the method according to any one of embodiments 1 to 22, a first exercise module is provided, the first exercise module including at least one of moderate, aerobic and acute exercise tasks.

[0214] Embodiment 24. In the method according to embodiment 23, a first exercise module is provided that includes a moderate exercise task, and maintaining, optimizing, or enhancing the subject's immune system includes stimulating NK cells.

[0215] Embodiment 25 In the method according to any one of embodiments 1 to 24, the moderate exercise is determined based on at least age and / or target heart rate.

[0216] In the method according to embodiment 25, moderate exercise for a subject of about 15 years of age is about 126 to about 150 beats per minute (bpm). moderate exercise for a subject about 20 years old includes a target heart rate of about 124 to about 147 bpm, moderate exercise for a subject about 25 years old includes a target heart rate of about 122 to about 145 bpm, moderate exercise for a subject about 30 years old includes a target heart rate of about 120 to about 142 bpm, moderate exercise for a subject about 35 years old includes a target heart rate of about 117 to about 139 bpm, moderate exercise for a subject about 40 years old includes a target heart rate of about 115 to about 137 bpm, moderate exercise for a subject about 45 years old includes a target heart rate of about 113 to about 134 bpm, moderate exercise for a subject about 50 years old includes a target heart rate of about 111 to about 132 bpm, and moderate exercise for a subject about 55 years old includes a target heart rate of about 115 to about 137 bpm. moderate exercise for a subject aged about 60 years includes a target heart rate of about 107 to about 127 bpm, moderate exercise for a subject aged about 65 years includes a target heart rate of about 105 to about 124 bpm, moderate exercise for a subject aged about 70 years includes a target heart rate of about 102 to about 122 bpm, moderate exercise for a subject aged about 75 years includes a target heart rate of about 100 to about 119 bpm, moderate exercise for a subject aged about 80 years includes a target heart rate of about 98 to about 117 bpm, moderate exercise for a subject aged about 85 years includes a target heart rate of about 96 to about 114 bpm, and moderate exercise for a subject aged about 95 years includes a target heart rate of about 92 to about 109 bpm.

[0217] Embodiment 27. In the method according to embodiment 25 or embodiment 26, the target heart rate is determined, at least in part, based on feedback from an exercise performed prior to the provision.

[0218] Embodiment 28. In the method according to embodiment 27, an increase in the subject's heart rate relative to the target heart rate for the moderate exercise module by more than 1 bpm, more than 2 bpm, more than 3 bpm, more than 4 bpm, more than 5 bpm, more than 6 bpm, more than 7 bpm, more than 8 bpm, more than 9 bpm, more than 10 bpm, more than 15 bpm or more than 20 bpm causes a decrease in the target heart rate for a subsequent moderate exercise module.

[0219] Embodiment 29. In the method according to embodiment 27, a decrease in the subject's heart rate relative to the target heart rate for a moderate exercise module by more than 1 bpm, more than 2 bpm, more than 3 bpm, more than 4 bpm, more than 5 bpm, more than 6 bpm, more than 7 bpm, more than 8 bpm, more than 9 bpm, more than 10 bpm, more than 15 bpm or more than 20 bpm causes an increase in the target heart rate for a subsequent moderate exercise module.

[0220] In the method according to any one of the first to twenty-nine embodiments, the moderate exercise is a measure of heart rate (HR), repetition maximum (RM), metabolic equivalents (METs), and maximum oxygen uptake (VO 2max ) / oxygen reserve (VO2R), or rate of perceived exertion (RPE).

[0221] Embodiment 31. In a method according to any one of embodiments 1 to 30, a first exercise module is provided that includes aerobic exercise and / or an acute exercise challenge, and maintaining, optimizing or enhancing the subject's immune system includes T cell boosting.

[0222] Embodiment 32. In a method according to any one of embodiments 1 to 31, a first exercise module is provided that includes an aerobic exercise and / or acute exercise task, and a level of aerobic exercise and / or acute exercise is determined prior to providing the first exercise module.

[0223] Embodiment 33. In the method according to any one of embodiments 1 to 32, a first exercise module is provided that includes an aerobic exercise and / or acute exercise task, and the level of aerobic exercise and / or acute exercise is measured using HR, RM, METs, VO 2max It is determined based on at least one of the following: / VO2R, or RPE.

[0224] Embodiment 34. In a method according to any one of embodiments 1 to 33, a first exercise module is provided that includes an aerobic exercise task, and maintaining, optimizing or enhancing the subject's immune system includes expressing CD4+ T cells to activate the immune system.

[0225] Embodiment 35. In a method according to any one of embodiments 1 to 34, a first exercise module is provided that includes an acute exercise task, and maintaining, optimizing or enhancing the subject's immune system includes removing existing T cells to reserve a T cell area for new T cells.

[0226] Embodiment 36. In the method according to any one of embodiments 1 to 35, the first exercise module includes at least one first exercise task for simultaneous aerobic and acute exercise.

[0227] Embodiment 37. In a method according to any one of embodiments 1 to 36, the one or more first tasks include tasks for resistance exercise, concurrent exercise, and / or benchmark exercise.

[0228] Embodiment 38. In the method according to embodiment 37, the benchmark exercise comprises one or more selected from the group consisting of jumping jacks, squats, and push-ups.

[0229] Embodiment 39. In the method according to embodiment 37 or embodiment 38, the method further comprises repeating the benchmark exercise at least one time in succession.

[0230] Embodiment 40. In the method according to any one of embodiments 1 to 39, the one or more first tasks include one or more tasks for walking, cycling, aerobic dancing, and / or swimming.

[0231] Embodiment 41. In a method according to any one of embodiments 1 to 40, a first vagus nerve stimulation module is provided, the vagus nerve stimulation module including one or more first tasks for stimulating the subject's parasympathetic nervous system.

[0232] Embodiment 42 In the method according to embodiment 41, maintaining, optimizing or enhancing the immune system of the subject comprises accelerating B-cell maturation and / or B-cell differentiation into plasma cells.

[0233] Embodiment 43 In the method according to embodiment 1 or embodiment 42, maintaining, optimizing, or enhancing the subject's immune system comprises increasing the number of reactive cells of the subject's immune system.

[0234] Embodiment 44. In a method according to any one of embodiments 1 to 43, a first vagus nerve stimulation module is provided, the vagus nerve stimulation module including at least one task selected from the group consisting of sensory stimulation tasks for vision, hearing, touch, taste and smell.

[0235] Embodiment 45. In a method according to embodiment 44, the vagus nerve stimulation module includes one or more sensory stimulation tasks for vision, and the one or more sensory stimulation tasks for vision include one or more tasks for viewing one or more figures to stimulate the autonomic nervous system.

[0236] Embodiment 46 In the method according to embodiment 45, the electronic device receives and displays the picture.

[0237] Embodiment 47. In the method according to embodiment 45 or embodiment 46, the picture includes one or more images for inducing fear in the subject.

[0238] Embodiment 48. In a method according to any one of embodiments 44 to 47, the vagus nerve stimulation module includes one or more sensory stimulation tasks for hearing, and the one or more sensory stimulation tasks for hearing include one or more tasks for listening to one or more sounds to induce fear or relaxation.

[0239] Embodiment 49. In the method according to embodiment 48, the one or more sounds for inducing relaxation include white noise.

[0240] Embodiment 50. In the method according to embodiment 48 or embodiment 49, the electronic device receives and plays the sound.

[0241] Embodiment 51. In a method according to any one of embodiments 44 to 50, the vagus nerve stimulation module includes one or more sensory stimulation tasks for touch, and the one or more sensory stimulation tasks for touch include one or more tasks for abdominal breathing, controlling breathing rate, breath holding, cold compresses, dipping the face in cold water, coughing, and skin massage.

[0242] Embodiment 52. In a method according to any one of embodiments 44 to 51, the vagus nerve stimulation module includes one or more sensory stimulation tasks for touch, and the one or more sensory stimulation tasks for touch include one or more tasks for controlling respiration rate.

[0243] Embodiment 53. In a method according to any one of embodiments 44 to 52, the vagus nerve stimulation module includes one or more sensory stimulation tasks for the sense of smell, and the one or more sensory stimulation tasks for the sense of smell include one or more sensory stimulation tasks for relieving tension.

[0244] Embodiment 54. In the method according to any one of embodiments 1 to 53, the electronic device is configured to emit a scent for aroma therapy.

[0245] Embodiment 55. In the method according to any one of embodiments 1 to 54, the subject is about 45 years of age or younger.

[0246] Embodiment 56 In the method according to embodiment 55, the first motor module is provided before the first vagus nerve stimulation module.

[0247] Embodiment 57. In the method according to any one of embodiments 20 to 56, the server receives one or more second challenges from an external reviewer.

[0248] Embodiment 58 In the method according to embodiment 57, the external reviewers include medical personnel.

[0249] Embodiment 59. In the method according to embodiment 58, the external reviewer includes an artificial intelligence (AI).

[0250] Embodiment 60. In a method according to any one of embodiments 20 to 59, the sensor includes one or more of a camera, an accelerometer, a magnetometer, a light sensor, a microphone, a proximity sensor, a touch sensor, a gyroscope, a GPS (Global Positioning System) sensor, an ambient light sensor, a fingerprint sensor, a pedometer, a heart rate sensor, a motion sensor, and a thermometer.

[0251] Embodiment 61. In the method according to any one of embodiments 20 to 60, the sensor includes a touch sensor, and the subject provides the compliance information to the electronic device using the touch sensor.

[0252] Embodiment 62 In the method according to any one of embodiments 20 to 61, the sensor includes a motion sensor or an accelerometer, and the device detects the compliance information using the motion sensor or the accelerometer.

[0253] Embodiment 63. In the method according to any one of embodiments 20 to 62, the electronic device is selected from the group consisting of a smartphone, a smart watch, smart jewelry, and a head-mounted display.

[0254] Embodiment 64. The method according to any one of embodiments 1 to 63, wherein the method further comprises repeating the method twice per week, three times per week, or more than three times per week.

[0255] Embodiment 65. A method according to any one of embodiments 1 to 64, wherein the method treats or prevents a disease in a subject.

[0256] Embodiment 66. A system for maintaining, optimizing or enhancing a subject's immune system, the system including an electronic device configured to execute a digital application including a first motor module and / or a first vagus nerve stimulation module for maintaining, optimizing or enhancing the subject's immune system, a healthcare provider portal configured to provide one or more options to a healthcare provider to perform one or more tasks for prescribing a treatment for maintaining, optimizing or enhancing the subject's immune system based on information received from the digital application, and an administration portal configured to provide one or more options to an administrator of the system to perform one or more tasks for managing access to the system by healthcare providers.

[0257] Embodiment 67. In the system according to embodiment 66, maintaining, optimizing or enhancing the immune system activates or increases the production of natural killer (NK) cells in the subject.

[0258] Embodiment 68 In the system according to embodiment 66 or embodiment 67, maintaining, optimizing or enhancing the immune system reduces changes in central T cell numbers in a subject.

[0259] Embodiment 69 In a system according to any one of embodiments 66 to 68, maintaining, optimizing or enhancing the immune system reduces changes in the number of effector T cells within a subject.

[0260] Embodiment 70 In a system according to any one of embodiments 66 to 69, maintaining, optimizing or enhancing the immune system reduces changes in the number of effective memory T cells in a subject.

[0261] Embodiment 71 In a system according to any one of embodiments 66 to 70, maintaining, optimizing or enhancing the immune system activates or increases the production of naive CD4 T cells in the subject.

[0262] Embodiment 72 In the system according to embodiment 71, the naive T cells are activated or expanded within one month of provision.

[0263] Embodiment 73 In a system according to any one of embodiments 66 to 72, maintaining, optimizing or enhancing the immune system reduces changes in central CD4 T cell counts in a subject.

[0264] Embodiment 74 In a system according to any one of embodiments 66 to 73, maintaining, optimizing or enhancing the immune system reduces changes in effective CD4 T cell counts in a subject.

[0265] Embodiment 75 In a system according to any one of embodiments 66 to 74, maintaining, optimizing or enhancing the immune system reduces changes in memory CD4 T cell counts in a subject.

[0266] Embodiment 76 In a system according to any one of embodiments 66 to 75, maintaining, optimizing or enhancing the immune system reduces changes in the number of naive CD8 T cells in a subject.

[0267] Embodiment 77 In a system according to any one of embodiments 66 to 76, maintaining, optimizing or enhancing the immune system reduces changes in central CD8 T cell counts within a subject.

[0268] Embodiment 78 In a system according to any one of embodiments 66 to 77, maintaining, optimizing or enhancing the immune system reduces changes in the number of effective CD8 T cells in a subject.

[0269] Embodiment 79 In a system according to any one of embodiments 66 to 78, maintaining, optimizing or enhancing the immune system reduces changes in the number of effective memory CD8 T cells in a subject.

[0270] Embodiment 80. In a system according to any one of embodiments 66 to 79, maintaining, optimizing or enhancing the immune system comprises activating or increasing the generation of CD4 Treg cells in the subject.

[0271] Embodiment 81 In a system according to any one of embodiments 66 to 80, maintaining, optimizing or enhancing the immune system comprises maturing and activating naive B cells in a subject.

[0272] Embodiment 82 In a system according to any one of embodiments 66 to 81, maintaining, optimizing or enhancing the immune system increases naive B cells in a subject.

[0273] Embodiment 83 In a system according to any one of embodiments 66 to 82, maintaining, optimizing or enhancing the immune system increases memory B cells in a subject.

[0274] Embodiment 84 In a system according to any one of embodiments 66 to 83, maintaining, optimizing or enhancing the immune system reduces plasma B cells in a subject.

[0275] Embodiment 85. In a system according to any one of embodiments 66 to 84, the digital application instructs a processor of the electronic device to perform operations including generating a digital therapeutic module including a first exercise module and / or a first vagus nerve stimulation module for maintaining, optimizing, or enhancing the immune system based on age and / or target heart rate.

[0276] Embodiment 86. In a system according to any one of embodiments 66 to 85, the electronic device or other electronic device is further configured to execute a digital application including a second exercise module and / or a second vagus nerve stimulation module for maintaining, optimizing or enhancing the subject's immune system, each of the second modules including one or more second tasks, and the electronic device (i) includes a sensor for sensing the subject's compliance with a first task of the first module, (ii) transmits compliance information to a server based on the compliance, and (iii) receives one or more second tasks from the server based on the compliance information.

[0277] Embodiment 87. In a system according to any one of embodiments 66 to 86, a delay time of at least 3 hours is provided to the first motor module and the first vagus nerve stimulation module.

[0278] Embodiment 88. In a system according to any one of embodiments 66 to 87, a first exercise module is provided, the exercise module including one or more first tasks for stimulating the subject's sympathetic nervous system.

[0279] Embodiment 89. In a system according to any one of embodiments 66 to 88, a first exercise module is provided, the first exercise module including at least one of moderate, aerobic and acute exercise tasks.

[0280] Embodiment 90. In the system according to embodiment 89, a first exercise module is provided that includes a moderate exercise task, and maintaining, optimizing, or enhancing the subject's immune system includes stimulating NK cells.

[0281] Embodiment 91. In the system according to embodiment 90, moderate exercise is determined based on at least age and / or target heart rate.

[0282] In the system according to embodiment 91, moderate exercise for a subject about 15 years old is about 126 to about 150 beats per minute (bpm). moderate exercise for a subject about 20 years old includes a target heart rate of about 124 to about 147 bpm, moderate exercise for a subject about 25 years old includes a target heart rate of about 122 to about 145 bpm, moderate exercise for a subject about 30 years old includes a target heart rate of about 120 to about 142 bpm, moderate exercise for a subject about 35 years old includes a target heart rate of about 117 to about 139 bpm, moderate exercise for a subject about 40 years old includes a target heart rate of about 115 to about 137 bpm, moderate exercise for a subject about 45 years old includes a target heart rate of about 113 to about 134 bpm, moderate exercise for a subject about 50 years old includes a target heart rate of about 111 to about 132 bpm, and moderate exercise for a subject about 55 years old includes a target heart rate of about 115 to about 137 bpm. moderate exercise for a subject aged about 60 years includes a target heart rate of about 107 to about 127 bpm, moderate exercise for a subject aged about 65 years includes a target heart rate of about 105 to about 124 bpm, moderate exercise for a subject aged about 70 years includes a target heart rate of about 102 to about 122 bpm, moderate exercise for a subject aged about 75 years includes a target heart rate of about 100 to about 119 bpm, moderate exercise for a subject aged about 80 years includes a target heart rate of about 98 to about 117 bpm, moderate exercise for a subject aged about 85 years includes a target heart rate of about 96 to about 114 bpm, and moderate exercise for a subject aged about 95 years includes a target heart rate of about 92 to about 109 bpm.

[0283] Embodiment 93. In a system according to embodiment 91 or embodiment 92, the target heart rate is determined based at least in part on feedback from a prior exercise provided.

[0284] Embodiment 94. In a system according to embodiment 93, an increase in the subject's heart rate relative to the target heart rate for a moderate exercise module by more than 1 bpm, more than 2 bpm, more than 3 bpm, more than 4 bpm, more than 5 bpm, more than 6 bpm, more than 7 bpm, more than 8 bpm, more than 9 bpm, more than 10 bpm, more than 15 bpm or more than 20 bpm causes a decrease in the target heart rate for a subsequent moderate exercise module.

[0285] Embodiment 95. In a system according to embodiment 93, a decrease in the subject's heart rate relative to the target heart rate for a moderate exercise module by more than 1 bpm, more than 2 bpm, more than 3 bpm, more than 4 bpm, more than 5 bpm, more than 6 bpm, more than 7 bpm, more than 8 bpm, more than 9 bpm, more than 10 bpm, more than 15 bpm or more than 20 bpm causes an increase in the target heart rate for a subsequent moderate exercise module.

[0286] In the system according to any one of the embodiments 66 to 95, moderate exercise is performed to improve heart rate (HR), repetition maximum (RM), metabolic equivalents (METs), and maximum oxygen uptake (VO 2max ) / oxygen reserve (VO2R), or rate of perceived exertion (RPE).

[0287] Embodiment 97. In a system according to any one of embodiments 66 to embodiment 96, a first exercise module is provided that includes aerobic exercise and / or an acute exercise task, and maintaining, optimizing or enhancing the subject's immune system includes T cell boosting.

[0288] Embodiment 98. In a system according to any one of embodiments 66 to 97, a first exercise module including an aerobic exercise and / or acute exercise task is provided, and prior to providing the module, a level of aerobic exercise and / or acute exercise is determined.

[0289]

[0046] Embodiment 99. In the system according to any one of embodiments 66 to 98, a first exercise module is provided that includes an aerobic exercise and / or acute exercise task, and the level of aerobic exercise and / or acute exercise is determined based on HR, RM, METs, VO 2max It is determined based on at least one of the following: / VO2R, or RPE.

[0290] Embodiment 100. In a system according to any one of embodiments 66 to embodiment 99, a first exercise module including an aerobic exercise task is provided, and maintaining, optimizing or enhancing the subject's immune system includes expressing CD4+ T cells to activate the immune system.

[0291] Embodiment 101. In a system according to any one of embodiments 66 to 100, a first exercise module including an acute exercise task is provided, and maintaining, optimizing or enhancing the subject's immune system includes removing existing T cells to reserve a T cell area for new T cells.

[0292] Embodiment 102. In a system according to any one of embodiments 66 to 101, the first exercise module includes at least one first exercise task for simultaneous aerobic and acute exercise.

[0293] Embodiment 103. In a system according to any one of embodiments 66 to 102, the one or more first tasks include tasks for resistance exercise, simultaneous exercise and / or benchmark exercise.

[0294] Embodiment 104. In the system according to embodiment 103, the benchmark exercise includes one or more selected from the group consisting of jumping jacks, squats, and push-ups.

[0295] Embodiment 105. In the system according to embodiment 103 or embodiment 104, the system further includes a step of repeating the benchmark exercise at least one consecutive time.

[0296] Embodiment 106. In a system according to any one of embodiments 66 to 105, the one or more first tasks include one or more tasks for walking, cycling, aerobic dancing, and / or swimming.

[0297] Embodiment 107. In a system according to any one of embodiments 66 to 106, a first vagus nerve stimulation module is provided, which includes one or more first tasks for stimulating the subject's parasympathetic nervous system.

[0298] Embodiment 108. In the system according to embodiment 107, maintaining, optimizing, or enhancing the subject's immune system includes accelerating B-cell maturation and / or B-cell differentiation into plasma cells.

[0299] Embodiment 109 In the system according to embodiment 107 or embodiment 108, maintaining, optimizing, or enhancing the subject's immune system includes increasing the number of reactive cells of the subject's immune system.

[0300] Embodiment 110. In a system according to any one of embodiments 66 to 109, a first vagus nerve stimulation module is provided, the vagus nerve stimulation module including at least one task selected from the group consisting of sensory stimulation tasks for vision, hearing, touch, taste and smell.

[0301] Embodiment 111. In a system according to embodiment 110, the vagus nerve stimulation module includes one or more sensory stimulation tasks for vision, and the one or more sensory stimulation tasks for vision include one or more tasks for viewing one or more pictures to stimulate the autonomic nervous system.

[0302] Embodiment 112. In the system according to embodiment 111, the electronic device receives and displays a picture.

[0303] Embodiment 113 In the system according to embodiment 111 or embodiment 112, the picture includes one or more images for inducing fear in the subject.

[0304] Embodiment 114. In a system according to any one of embodiments 110 to 113, the vagus nerve stimulation module includes one or more sensory stimulation tasks for hearing, and the one or more sensory stimulation tasks for hearing include one or more tasks for listening to one or more sounds to induce fear or relaxation.

[0305] Embodiment 115. In the system according to embodiment 114, the one or more sounds for inducing relaxation include white noise.

[0306] Embodiment 116 In the system according to embodiment 114 or embodiment 115, the electronic device receives and plays sound.

[0307] Embodiment 117. In a system according to any one of embodiments 110 to 116, the vagus nerve stimulation module includes one or more sensory stimulation tasks for touch, and the one or more sensory stimulation tasks for touch include one or more tasks for abdominal breathing, controlling breathing rate, breath holding, cold compresses, dipping the face in cold water, coughing, and skin massage.

[0308] Embodiment 118. In a system according to any one of embodiments 110 to 117, the vagus nerve stimulation module includes one or more sensory stimulation tasks for touch, and the one or more sensory stimulation tasks for touch include one or more tasks for controlling respiration rate.

[0309] Embodiment 119. In a system according to any one of embodiments 110 to 118, the vagus nerve stimulation module includes one or more sensory stimulation tasks for the sense of smell, and the one or more sensory stimulation tasks for the sense of smell include one or more tasks for relieving tension.

[0310] Embodiment 120. In a system according to any one of embodiments 66 to 119, the electronic device is configured to emit a scent for aromatherapy.

[0311] Embodiment 121. In a system according to any one of embodiments 66 to 120, the subject is less than about 45 years old.

[0312] Embodiment 122. In the system according to embodiment 121, a first motor module is provided before the first vagus nerve stimulation module.

[0313] Embodiment 123. In a system according to any one of embodiments 66 to 122, the server receives one or more second tasks from an external reviewer.

[0314] Embodiment 124. In the system according to embodiment 123, the external reviewers include medical personnel.

[0315] Embodiment 125. In the system according to embodiment 124, the external reviewer includes artificial intelligence (AI).

[0316] Embodiment 126. In a system according to any one of embodiments 66 to 125, the sensor includes one or more of a camera, an accelerometer, a magnetometer, a light sensor, a microphone, a proximity sensor, a touch sensor, a gyroscope, a GPS (Global Positioning System) sensor, an ambient light sensor, a fingerprint sensor, a pedometer, a heart rate sensor, a motion sensor, and a thermometer.

[0317] Embodiment 127. In a system according to any one of embodiments 66 to 126, the sensor includes a touch sensor, and the subject provides compliance information to the electronic device using the touch sensor.

[0318] Embodiment 128. In a system according to any one of embodiments 66 to 127, the sensor includes a motion sensor or an accelerometer, and the device detects compliance information using the motion sensor or the accelerometer.

[0319] Embodiment 129. In a system according to any one of embodiments 66 to 128, the electronic device is selected from the group consisting of a smartphone, a smart watch, smart jewelry, and a head-mounted display.

[0320] Embodiment 130. A system according to any one of embodiments 66 to 129, wherein the system further includes repeating the method using the system twice per week, three times per week, or more than three times per week.

[0321] Embodiment 131. Optionally, a computing system for maintaining, optimizing or enhancing a subject's immune system includes a display configured to provide to the subject a first exercise module and / or a first vagus nerve stimulation module, each of the first modules including one or more first tasks to be followed by the subject, a transmitter configured to transmit compliance information to a server, and a receiver configured to receive from the server one or more second tasks based on the compliance information, the display further configured to provide to the subject a second exercise module and / or a second vagus nerve stimulation module, each of the second modules including one or more second tasks.

[0322] Embodiment 132. In a computing system according to embodiment 131, maintaining, optimizing or enhancing the immune system activates or increases the production of natural killer (NK) cells in the subject.

[0323] Embodiment 133. In a computing system according to embodiment 131 or embodiment 132, maintaining, optimizing or enhancing the immune system reduces changes in central T cell counts within a subject.

[0324] Embodiment 134. In a computing system according to any one of embodiments 131 to 133, maintaining, optimizing or enhancing the immune system reduces changes in the number of effector T cells within a subject.

[0325] Embodiment 135. In a computing system according to any one of embodiments 131 to 134, maintaining, optimizing or enhancing the immune system reduces changes in the number of effective memory T cells in a subject.

[0326] Embodiment 136 In a computing system according to any one of embodiments 131 to 135, maintaining, optimizing or strengthening the immune system activates or increases the production of naive CD4 T cells in a subject.

[0327] Embodiment 137 In the computing system according to embodiment 136, the naive T cells are activated or expanded within one month of provision.

[0328] Embodiment 138. In a computing system according to any one of embodiments 131 to 137, maintaining, optimizing or enhancing the immune system reduces changes in central CD4 T cell counts within a subject.

[0329] Embodiment 139. In a computing system according to any one of embodiments 131 to 138, maintaining, optimizing or enhancing the immune system reduces changes in effective CD4 T cell counts within a subject.

[0330] Embodiment 140. In a computing system according to any one of embodiments 131 to 139, maintaining, optimizing or enhancing the immune system reduces changes in memory CD4 T cell counts in a subject.

[0331] Embodiment 141. In a computing system according to any one of embodiments 131 to 140, maintaining, optimizing or enhancing the immune system reduces changes in the number of naive CD8 T cells within a subject.

[0332] Embodiment 142. In a computing system according to any one of embodiments 131 to 141, maintaining, optimizing or enhancing the immune system reduces changes in central CD8 T cell counts within a subject.

[0333] Embodiment 143. In a computing system according to any one of embodiments 131 to 142, maintaining, optimizing or enhancing the immune system reduces changes in the number of effective CD8 T cells in a subject.

[0334] Embodiment 144. In a computing system according to any one of embodiments 131 to 143, maintaining, optimizing or enhancing the immune system reduces changes in the number of effective memory CD8 T cells in a subject.

[0335] Embodiment 145. In a computing system according to any one of embodiments 131 to 144, maintaining, optimizing or enhancing the immune system activates or increases the production of CD4 Treg cells in a subject.

[0336] Embodiment 146 In a computing system according to any one of embodiments 131 to 145, maintaining, optimizing or enhancing the immune system comprises activating maturation of naive B cells in a subject.

[0337] Embodiment 147. In a computing system according to any one of embodiments 131 to 146, maintaining, optimizing or enhancing the immune system increases naive B cells in a subject.

[0338] Embodiment 148. In a computing system according to any one of embodiments 131 to 147, maintaining, optimizing or enhancing the immune system increases memory B cells in a subject.

[0339] Embodiment 149. In a computing system according to any one of embodiments 131 to 148, maintaining, optimizing or enhancing the immune system reduces plasma B cells in a subject.

[0340] Embodiment 150. In a computing system according to any one of embodiments 131 to 149, the system further includes a sensor configured to sense the subject's compliance with the task of the first module and generate compliance information.

[0341] Embodiment 151. In a computing system according to any one of embodiments 131 to 150, a delay time of at least 3 hours is provided to the first motor module and the first vagus nerve stimulation module.

[0342] Embodiment 152. In a computing system according to any one of embodiments 131 to 151, a first motor module is provided, the motor module including one or more first tasks for stimulating the subject's sympathetic nervous system.

[0343] Embodiment 153. In a computing system according to any one of embodiments 131 to 152, a first exercise module is provided, and the first exercise module includes at least one of moderate, aerobic and acute exercise tasks.

[0344] Embodiment 154. In a computing system according to embodiment 153, a first exercise module is provided that includes a moderate exercise task, and maintaining, optimizing, or enhancing the subject's immune system includes stimulating NK cells.

[0345] Embodiment 155. In a computing system according to any one of embodiments 131 to 154, moderate exercise is determined based on at least age and / or target heart rate.

[0346] In the computing system according to embodiment 155, moderate exercise for a subject about 15 years old is about 126 to about 150 beats per minute (bpm). moderate exercise for a subject about 20 years old includes a target heart rate of about 124 to about 147 bpm, moderate exercise for a subject about 25 years old includes a target heart rate of about 122 to about 145 bpm, moderate exercise for a subject about 30 years old includes a target heart rate of about 120 to about 142 bpm, moderate exercise for a subject about 35 years old includes a target heart rate of about 117 to about 139 bpm, moderate exercise for a subject about 40 years old includes a target heart rate of about 115 to about 137 bpm, moderate exercise for a subject about 45 years old includes a target heart rate of about 113 to about 134 bpm, moderate exercise for a subject about 50 years old includes a target heart rate of about 111 to about 132 bpm, and moderate exercise for a subject about 55 years old includes a target heart rate of about 115 to about 137 bpm. moderate exercise for a subject aged about 60 years includes a target heart rate of about 107 to about 127 bpm, moderate exercise for a subject aged about 65 years includes a target heart rate of about 105 to about 124 bpm, moderate exercise for a subject aged about 70 years includes a target heart rate of about 102 to about 122 bpm, moderate exercise for a subject aged about 75 years includes a target heart rate of about 100 to about 119 bpm, moderate exercise for a subject aged about 80 years includes a target heart rate of about 98 to about 117 bpm, moderate exercise for a subject aged about 85 years includes a target heart rate of about 96 to about 114 bpm, and moderate exercise for a subject aged about 95 years includes a target heart rate of about 92 to about 109 bpm.

[0347] Embodiment 157. In a computing system according to embodiment 155 or embodiment 156, the target heart rate is determined based at least in part on feedback from a prior exercise provided.

[0348] Embodiment 158. In a computing system according to embodiment 157, an increase in the subject's heart rate relative to the target heart rate for a moderate exercise module by more than 1 bpm, more than 2 bpm, more than 3 bpm, more than 4 bpm, more than 5 bpm, more than 6 bpm, more than 7 bpm, more than 8 bpm, more than 9 bpm, more than 10 bpm, more than 15 bpm or more than 20 bpm causes a decrease in the target heart rate for a subsequent moderate exercise module.

[0349] Embodiment 159. In a computing system according to embodiment 157, a decrease in the subject's heart rate relative to the target heart rate for a moderate exercise module by more than 1 bpm, more than 2 bpm, more than 3 bpm, more than 4 bpm, more than 5 bpm, more than 6 bpm, more than 7 bpm, more than 8 bpm, more than 9 bpm, more than 10 bpm, more than 15 bpm or more than 20 bpm causes an increase in the target heart rate for a subsequent moderate exercise module.

[0350] In the computing system according to any one of the embodiments 131 to 159, moderate exercise is performed by measuring heart rate (HR), maximum repetitions (RM), metabolic equivalents (METs), maximum oxygen uptake (VO 2max ) / oxygen reserve (VO2R), or rate of perceived exertion (RPE).

[0351] Embodiment 161. In a computing system according to any one of embodiments 131 to 160, a first exercise module is provided that includes aerobic exercise and / or an acute exercise challenge, and maintaining, optimizing or enhancing the subject's immune system includes T cell boosting.

[0352] Embodiment 162. In a computing system according to any one of embodiments 131 to 161, a first exercise module including an aerobic exercise and / or acute exercise task is provided, and prior to providing the module, a level of aerobic exercise and / or acute exercise is determined.

[0353] In the computing system according to any one of the embodiments 131 to 162, a first exercise module including an aerobic exercise and / or acute exercise task is provided, and the aerobic exercise and / or acute exercise level is determined based on HR, RM, METs, VO 2max It is determined based on at least one of the following: / VO2R, or RPE.

[0354] Embodiment 164. In a computing system according to any one of embodiments 131 to embodiment 163, a first exercise module including an aerobic exercise task is provided, and maintaining, optimizing or enhancing the subject's immune system includes expressing CD4+ T cells to activate the immune system.

[0355] Embodiment 165. In a computing system according to any one of embodiments 131 to embodiment 164, a first exercise module including an acute exercise task is provided, and maintaining, optimizing or enhancing the subject's immune system includes removing existing T cells to reserve a T cell area for new T cells.

[0356] Embodiment 166 In a computing system according to any one of embodiments 131 to 165, the first exercise module includes at least one first exercise task for simultaneous aerobic and acute exercise.

[0357] Embodiment 167. In a computing system according to any one of embodiments 131 to 166, the one or more first tasks include tasks for resistance exercise, simultaneous exercise and / or benchmark exercise.

[0358] Embodiment 168 In the computing system according to embodiment 167, the benchmark exercise includes one or more selected from the group consisting of jumping jacks, squats, and push-ups.

[0359] Embodiment 169. In the computing system according to embodiment 167 or embodiment 168, the method further includes repeating the benchmark exercise at least one successive time.

[0360] Embodiment 170. In a computing system according to any one of embodiments 131 to 169, the one or more first tasks include one or more tasks for walking, cycling, aerobic dancing, and / or swimming.

[0361] Embodiment 171. In a computing system according to any one of embodiments 131 to 170, a first vagus nerve stimulation module is provided, the vagus nerve stimulation module including one or more first tasks for stimulating the subject's parasympathetic nervous system.

[0362] Embodiment 172. In a computing system according to embodiment 171, maintaining, optimizing, or enhancing the subject's immune system includes accelerating B-cell maturation and / or B-cell differentiation into plasma cells.

[0363] Embodiment 173. In a computing system according to embodiment 171 or embodiment 172, maintaining, optimizing, or enhancing the subject's immune system includes increasing the number of reactive cells of the subject's immune system.

[0364] Embodiment 174. In a computing system according to any one of embodiments 131 to embodiment 173, a first vagus nerve stimulation module is provided, the vagus nerve stimulation module including at least one task selected from the group consisting of sensory stimulation tasks for vision, hearing, touch, taste and smell.

[0365] Embodiment 175. In a computing system according to embodiment 174, the vagus nerve stimulation module includes one or more sensory stimulation tasks for vision, and the one or more sensory stimulation tasks for vision include one or more tasks for viewing one or more pictures to stimulate the autonomic nervous system.

[0366] Embodiment 176 In the computing system according to embodiment 175, the electronic device receives and displays a picture.

[0367] Embodiment 177. In the computing system according to embodiment 174 or embodiment 175, the picture includes one or more images for inducing fear in a subject.

[0368] Embodiment 178. In a computing system according to any one of embodiments 174 to 177, the vagus nerve stimulation module includes one or more sensory stimulation tasks for hearing, and the one or more sensory stimulation tasks for hearing include one or more tasks for listening to one or more sounds to induce fear or relaxation.

[0369] Embodiment 179. In the computing system according to embodiment 178, the one or more sounds for inducing relaxation include white noise.

[0370] Embodiment 180. In a computing system according to embodiment 178 or embodiment 179, an electronic device receives and plays sound.

[0371] Embodiment 181. In a computing system according to any one of embodiments 174 to 180, the vagus nerve stimulation module includes one or more sensory stimulation tasks for touch, and the one or more sensory stimulation tasks for touch include one or more tasks for abdominal breathing, controlling breathing rate, breath holding, cold compresses, dipping the face in cold water, coughing, and skin massage.

[0372] Embodiment 182. In a computing system according to any one of embodiments 174 to 181, the vagus nerve stimulation module includes one or more sensory stimulation tasks for touch, and the one or more sensory stimulation tasks for touch include one or more tasks for controlling respiration rate.

[0373] Embodiment 183. In a computing system according to any one of embodiments 174 to 182, the vagus nerve stimulation module includes one or more olfactory stimulation tasks for the sense of smell, and the one or more sensory stimulation tasks for the sense of smell include one or more tasks for relieving tension.

[0374] Embodiment 184. In a computing system according to any one of embodiments 131 to 183, the electronic device is configured to emit a scent for aromatherapy.

[0375] Embodiment 185. In a computing system according to any one of embodiments 131 to 184, the subject is approximately 45 years of age or younger.

[0376] Embodiment 186 In the computing system according to embodiment 185, a first motor module is provided before a first vagus nerve stimulation module.

[0377] Embodiment 187. In a computing system according to any one of embodiments 131 to 186, the sensor includes one or more of a camera, an accelerometer, a magnetometer, a light sensor, a microphone, a proximity sensor, a touch sensor, a gyroscope, a Global Positioning System (GPS) sensor, an ambient light sensor, a fingerprint sensor, a pedometer, a heart rate sensor, a motion sensor, and a thermometer.

[0378] Embodiment 188. In a computing system according to any one of embodiments 131 to 187, the sensor includes a touch sensor, and the subject uses the touch sensor to provide compliance information to the electronic device.

[0379] Embodiment 189. In a computing system according to any one of embodiments 131 to 188, the sensor includes a motion sensor or an accelerometer, and the device detects compliance information using the motion sensor or the accelerometer.

[0380] Embodiment 190. In a computing system according to any one of embodiments 131 to 189, the electronic device is selected from the group consisting of a smartphone, a smart watch, smart jewelry, and a head-mounted display.

[0381] Embodiment 191. In a computing system according to any one of embodiments 131 to 190, the computing system further includes repeating the method using the computing system twice per week, three times per week, or more than three times per week.

[0382] Embodiment 192. Optionally, a non-transitory computer readable medium having stored thereon software instructions for maintaining, optimizing or enhancing a subject's immune system, the software instructions, when executed by a processor, cause the processor to display a first exercise module and / or a first vagus nerve stimulation module to the subject via the electronic device, each of the first modules including a task for the subject to follow, sense the subject's compliance with the tasks of the first module via a sensor of the electronic device, transmit compliance information to a server based on the compliance, receive one or more second tasks from the server based on the compliance information, and display a second exercise module and / or a second vagus nerve stimulation module to the subject, the second module including one or more second tasks.

[0383] Embodiment 193. In the non-transitory computer readable medium according to embodiment 192, maintaining, optimizing or enhancing the immune system activates or increases the production of natural killer (NK) cells in the subject.

[0384] Embodiment 194. In the non-transitory computer readable medium according to embodiment 192 or embodiment 193, maintaining, optimizing or enhancing the immune system reduces changes in central T cell numbers in a subject.

[0385] Embodiment 195. In a non-transitory computer readable medium according to any one of embodiments 192 to 194, maintaining, optimizing or enhancing the immune system reduces changes in the number of effector T cells in a subject.

[0386] Embodiment 196. In a non-transitory computer readable medium according to any one of embodiments 192 to 195, maintaining, optimizing or enhancing the immune system reduces changes in the number of effective memory T cells in a subject.

[0387] Embodiment 197. In a non-transitory computer-readable medium according to any one of embodiments 192 to 196, maintaining, optimizing or enhancing the immune system activates or increases the production of naive CD4 T cells in a subject.

[0388] Embodiment 198. In the non-transitory computer readable medium according to embodiment 197, the naive T cells are activated or expanded within one month of provision.

[0389] Embodiment 199. In a non-transitory computer readable medium according to any one of embodiments 192 to 198, maintaining, optimizing or enhancing the immune system reduces changes in central CD4 T cell counts in a subject.

[0390] Embodiment 200. In a non-transitory computer readable medium according to any one of embodiments 192 to 199, maintaining, optimizing or enhancing the immune system reduces changes in CD4 T cell counts in a subject.

[0391] Embodiment 201. In a non-transitory computer readable medium according to any one of embodiments 192 to 200, maintaining, optimizing or enhancing the immune system reduces changes in memory CD4 T cell counts in a subject.

[0392] Embodiment 202. In a non-transitory computer readable medium according to any one of embodiments 192 to 201, maintaining, optimizing or enhancing the immune system reduces changes in the number of naive CD8 T cells in a subject.

[0393] Embodiment 203. In a non-transitory computer readable medium according to any one of embodiments 192 to 202, maintaining, optimizing or enhancing the immune system reduces changes in central CD8 T cell counts in a subject.

[0394] Embodiment 204. In a non-transitory computer readable medium according to any one of embodiments 192 to 203, maintaining, optimizing or enhancing the immune system reduces changes in CD8 T cell counts in a subject.

[0395] Embodiment 205. In a non-transitory computer readable medium according to any one of embodiments 192 to 204, maintaining, optimizing or enhancing the immune system reduces changes in the number of effective memory CD8 T cells in a subject.

[0396] Embodiment 206. In a non-transitory computer readable medium according to any one of embodiments 192 to 205, maintaining, optimizing or enhancing the immune system activates or increases the generation of CD4 Treg cells in a subject.

[0397] Embodiment 207. In a non-transitory computer readable medium according to any one of embodiments 192 to 206, maintaining, optimizing or enhancing the immune system comprises maturing and activating naive B cells in a subject.

[0398] Embodiment 208. In a non-transitory computer readable medium according to any one of embodiments 192 to 207, maintaining, optimizing or enhancing the immune system increases naive B cells in a subject.

[0399] Embodiment 209. In a non-transitory computer readable medium according to any one of embodiments 192 to 208, maintaining, optimizing or enhancing the immune system increases memory B cells in a subject.

[0400] Embodiment 210. In a non-transitory computer readable medium according to any one of embodiments 192 to 209, maintaining, optimizing or enhancing the immune system reduces plasma B cells in a subject.

[0401] Embodiment 211. In the non-transitory computer-readable medium of embodiment 210, the processor further generates a digital therapeutic module including a first exercise module and / or a first vagus nerve stimulation module for maintaining, optimizing, or enhancing the immune system based on age and / or target heart rate.

[0402] Embodiment 212. In the non-transitory computer-readable medium according to embodiment 210 or embodiment 211, a delay time of at least 3 hours is provided for the first motor module and the first vagus nerve stimulation module.

[0403] Embodiment 213. In a non-transitory computer-readable medium according to any one of embodiments 192 to 212, a first exercise module is provided, and the exercise module includes one or more first tasks for stimulating the subject's sympathetic nervous system.

[0404] Embodiment 214. In a non-transitory computer-readable medium according to any one of embodiments 192 to 213, a first exercise module is provided, and the first exercise module includes at least one of moderate, aerobic and acute exercise tasks.

[0405] Embodiment 215. In a non-transitory computer-readable medium according to embodiment 214, a first exercise module is provided that includes a moderate exercise task, and maintaining, optimizing, or enhancing the subject's immune system includes stimulating NK cells.

[0406] Embodiment 216. In the non-transitory computer-readable medium according to any one of embodiments 192 to 215, the moderate exercise is determined based on at least age and / or target heart rate.

[0407] In the non-transitory computer-readable medium according to embodiment 216, moderate exercise for a subject of about 15 years of age is about 126 to about 150 beats per minute (bpm). moderate exercise for a subject about 20 years old includes a target heart rate of about 124 to about 147 bpm, moderate exercise for a subject about 25 years old includes a target heart rate of about 122 to about 145 bpm, moderate exercise for a subject about 30 years old includes a target heart rate of about 120 to about 142 bpm, moderate exercise for a subject about 35 years old includes a target heart rate of about 117 to about 139 bpm, moderate exercise for a subject about 40 years old includes a target heart rate of about 115 to about 137 bpm, moderate exercise for a subject about 45 years old includes a target heart rate of about 113 to about 134 bpm, moderate exercise for a subject about 50 years old includes a target heart rate of about 111 to about 132 bpm, and moderate exercise for a subject about 55 years old includes a target heart rate of about 115 to about 137 bpm. moderate exercise for a subject aged about 60 years includes a target heart rate of about 107 to about 127 bpm, moderate exercise for a subject aged about 65 years includes a target heart rate of about 105 to about 124 bpm, moderate exercise for a subject aged about 70 years includes a target heart rate of about 102 to about 122 bpm, moderate exercise for a subject aged about 75 years includes a target heart rate of about 100 to about 119 bpm, moderate exercise for a subject aged about 80 years includes a target heart rate of about 98 to about 117 bpm, moderate exercise for a subject aged about 85 years includes a target heart rate of about 96 to about 114 bpm, and moderate exercise for a subject aged about 95 years includes a target heart rate of about 92 to about 109 bpm.

[0408] Embodiment 218. In the non-transitory computer-readable medium according to embodiment 126 or embodiment 127, the target heart rate is determined based at least in part on feedback from an exercise performed prior to providing.

[0409] Embodiment 219. In the non-transitory computer readable medium according to embodiment 218, an increase in the subject's heart rate relative to the target heart rate for a moderate exercise module by more than 1 bpm, more than 2 bpm, more than 3 bpm, more than 4 bpm, more than 5 bpm, more than 6 bpm, more than 7 bpm, more than 8 bpm, more than 9 bpm, more than 10 bpm, more than 15 bpm or more than 20 bpm causes a decrease in the target heart rate for a subsequent moderate exercise module.

[0410] Embodiment 220. In the non-transitory computer readable medium according to embodiment 218, a decrease in the subject's heart rate relative to the target heart rate for a moderate exercise module by more than 1 bpm, more than 2 bpm, more than 3 bpm, more than 4 bpm, more than 5 bpm, more than 6 bpm, more than 7 bpm, more than 8 bpm, more than 9 bpm, more than 10 bpm, more than 15 bpm or more than 20 bpm causes an increase in the target heart rate for a subsequent moderate exercise module.

[0411] In the non-transitory computer-readable medium according to any one of the embodiments 192 to 220, moderate exercise is performed to improve heart rate (HR), maximum repetitions (RM), metabolic equivalents (METs), maximum oxygen uptake (VO 2max ) / oxygen reserve (VO2R), or rate of perceived exertion (RPE).

[0412] Embodiment 222. In a non-transitory computer-readable medium according to embodiment 221, a first exercise module is provided that includes aerobic exercise and / or an acute exercise challenge, and maintaining, optimizing, or enhancing the subject's immune system includes T cell boosting.

[0413] Embodiment 223. In a non-transitory computer-readable medium according to any one of embodiments 192 to 222, a first exercise module including an aerobic exercise and / or acute exercise task is provided, and prior to providing the module, a level of the aerobic exercise and / or acute exercise is determined.

[0414] In the non-transitory computer-readable medium according to any one of the embodiments 192 to 223, a first exercise module is provided that includes an aerobic exercise and / or acute exercise task, and the level of the aerobic exercise and / or acute exercise is determined based on HR, RM, METs, VO 2max It is determined based on at least one of the following: / VO2R, or RPE.

[0415] Embodiment 225. In a non-transitory computer-readable medium according to embodiment 224, a first exercise module is provided that includes an aerobic exercise task, and maintaining, optimizing, or enhancing the subject's immune system includes expressing CD4+ T cells to activate the immune system.

[0416] Embodiment 226. In a non-transitory computer-readable medium according to any one of embodiments 192 to 225, a first exercise module is provided that includes an acute exercise task, and maintaining, optimizing or enhancing the subject's immune system includes removing existing T cells to reserve a T cell area for new T cells.

[0417] Embodiment 227. In a non-transitory computer-readable medium according to any one of embodiments 192 to 226, the first exercise module includes at least one first exercise task for simultaneous aerobic and acute exercise.

[0418] Embodiment 228. In a non-transitory computer-readable medium according to any one of embodiments 192 to 227, the one or more first tasks include tasks for resistance exercise, simultaneous exercise and / or benchmark exercise.

[0419] Embodiment 229. In the non-transitory computer-readable medium according to embodiment 228, the benchmark exercise includes one or more selected from the group consisting of jumping jacks, squats, and push-ups.

[0420] Embodiment 230. In the non-transitory computer-readable medium according to embodiment 228 or embodiment 229, the method further includes repeating the benchmark exercise at least one time in succession.

[0421] Embodiment 231. In a non-transitory computer-readable medium according to any one of embodiments 192 to 230, the one or more first tasks include one or more tasks for walking, cycling, aerobic dancing, and / or swimming.

[0422] Embodiment 232. In a non-transitory computer-readable medium according to any one of embodiments 192 to 231, a first vagus nerve stimulation module is provided, and the vagus nerve stimulation module includes one or more first tasks for stimulating the subject's parasympathetic nervous system.

[0423] Embodiment 233. In the non-transitory computer-readable medium according to embodiment 232, maintaining, optimizing, or enhancing the subject's immune system includes accelerating B-cell maturation and / or B-cell differentiation into plasma cells.

[0424] Embodiment 234. In the non-transitory computer-readable medium according to embodiment 232 or embodiment 233, maintaining, optimizing, or enhancing the subject's immune system includes increasing the number of reactive cells of the subject's immune system.

[0425] Embodiment 235. In a non-transitory computer-readable medium according to any one of embodiments 192 to 234, a first vagus nerve stimulation module is provided, the vagus nerve stimulation module including at least one task selected from the group consisting of sensory stimulation tasks for vision, hearing, touch, taste and smell.

[0426] Embodiment 236. In a non-transitory computer-readable medium according to embodiment 235, the vagus nerve stimulation module includes one or more sensory stimulation tasks for vision, and the one or more sensory stimulation tasks for vision include one or more tasks for viewing one or more pictures to stimulate the autonomic nervous system.

[0427] Embodiment 237. In the non-transitory computer-readable medium according to embodiment 236, an electronic device receives and displays a picture.

[0428] Embodiment 238. In the non-transitory computer-readable medium according to embodiment 236 or embodiment 237, the picture includes one or more images for inducing fear in a subject.

[0429] Embodiment 239. In a non-transitory computer-readable medium according to any one of embodiments 192 to 238, the vagus nerve stimulation module includes one or more sensory stimulation tasks for hearing, and the one or more sensory stimulation tasks for hearing include one or more tasks for listening to one or more sounds to induce fear or relaxation.

[0430] Embodiment 240. In the non-transitory computer-readable medium according to embodiment 239, the one or more sounds for inducing relaxation include white noise.

[0431] Embodiment 241. In the non-transitory computer-readable medium according to embodiment 239 or embodiment 240, an electronic device receives and plays sound.

[0432] Embodiment 242. In a non-transitory computer-readable medium according to any one of embodiments 192 to 241, the vagus nerve stimulation module includes one or more sensory stimulation tasks for touch, and the one or more sensory stimulation tasks for touch include one or more tasks for abdominal breathing, controlling breathing rate, breath holding, cold compresses, dipping the face in cold water, coughing, and skin massage.

[0433] Embodiment 243. In a non-transitory computer-readable medium according to any one of embodiments 192 to 242, the vagus nerve stimulation module includes one or more sensory stimulation tasks for touch, and the one or more sensory stimulation tasks for touch include one or more tasks for controlling respiration rate.

[0434] Embodiment 244. In a non-transitory computer-readable medium according to any one of embodiments 192 to 243, the vagus nerve stimulation module includes one or more sensory stimulation tasks for the sense of smell, and the one or more sensory stimulation tasks for the sense of smell include one or more tasks for relieving tension.

[0435] Embodiment 245. In the non-transitory computer-readable medium according to any one of embodiments 192 to 244, the electronic device is configured to emit a scent for aromatherapy.

[0436] Embodiment 246. In the non-transitory computer-readable medium according to any one of embodiments 192 to 245, the subject is less than about 45 years of age.

[0437] Embodiment 247. In the non-transitory computer-readable medium according to embodiment 246, the first motor module is provided before the first vagus nerve stimulation module.

[0438] Embodiment 248. In a non-transitory computer-readable medium according to any one of embodiments 192 to 247, the server receives one or more second challenges from an external reviewer.

[0439] Embodiment 249. In the non-transitory computer-readable medium according to embodiment 248, the external reviewer includes a medical professional.

[0440] Embodiment 250. In the non-transitory computer-readable medium according to embodiment 249, the external reviewer includes an artificial intelligence (AI).

[0441] Embodiment 251. In a non-transitory computer-readable medium according to any one of embodiments 192 to 250, the sensor includes one or more of a camera, an accelerometer, a magnetometer, a light sensor, a microphone, a proximity sensor, a touch sensor, a gyroscope, a GPS (Global Positioning System) sensor, an ambient light sensor, a fingerprint sensor, a pedometer, a heart rate sensor, a motion sensor, and a thermometer.

[0442] Embodiment 252. In the non-transitory computer-readable medium according to any one of embodiments 192 to 251, the sensor includes a touch sensor, and the subject uses the touch sensor to provide compliance information to the electronic device.

[0443] Embodiment 253. In the non-transitory computer-readable medium according to any one of embodiments 192 to 252, the sensor includes a motion sensor or an accelerometer, and the device detects compliance information using the motion sensor or the accelerometer.

[0444] Embodiment 254. In the non-transitory computer-readable medium according to any one of embodiments 192 to 253, the electronic device is selected from the group consisting of a smartphone, a smart watch, smart jewelry, and a head-mounted display.

[0445] Embodiment 255. In a non-transitory computer-readable medium according to any one of embodiments 192 to 254, the non-transitory computer-readable medium further includes repeating the method twice per week, three times per week, or more than three times per week, using the non-transitory computer-readable medium.

Claims

1. 1. A digital apparatus for maintaining, optimizing, or enhancing the immune system of a subject, comprising: A memory for storing a digital application; a processor; The processor is configured to execute the digital application to provide at least one of a first exercise module or a first vagal nerve stimulation module, each of the first modules including one or more first tasks for the subject to follow.

2. The processor is further configured to provide at least one of a second motor module or a second vagus nerve stimulation module; each of the second modules includes one or more second tasks; The digital device for maintaining, optimizing or enhancing a subject's immune system as described in claim 1, further comprising: (i) a sensor for sensing the subject's compliance with a first task of the first module; (ii) transmitting compliance information to a server based on the compliance; and (iii) receiving the one or more second tasks from the server based on the compliance information.

3. 2. The digital device for maintaining, optimizing or enhancing a subject's immune system of claim 1, wherein a lag time is provided to the first motor module and the first vagus nerve stimulation module.

4. 2. The digital device for maintaining, optimizing or enhancing a subject's immune system as claimed in claim 1, wherein a first exercise module is provided, the first exercise module including one or more first tasks for stimulating the subject's sympathetic nervous system.

5. 2. The digital device for maintaining, optimizing or enhancing a subject's immune system as described in claim 1, wherein a first exercise module is provided, the first exercise module including at least one of moderate, aerobic and acute exercise tasks.

6. 2. The digital device for maintaining, optimizing or enhancing the immune system of a subject as described in claim 1, wherein a first vagus nerve stimulation module is provided, the first vagus nerve stimulation module including at least one task selected from the group consisting of sensory stimulation tasks related to sight, hearing, touch, taste, and smell.

7. 7. The digital device for maintaining, optimizing or enhancing a subject's immune system as described in claim 6, wherein the first vagus nerve stimulation module includes one or more sensory stimulation tasks for vision, and the one or more sensory stimulation tasks for vision include one or more tasks for viewing one or more figures to stimulate the autonomic nervous system.

8. 7. The digital device for maintaining, optimizing or enhancing a subject's immune system as described in claim 6, wherein the first vagus nerve stimulation module includes one or more sensory stimulation tasks for hearing, and the one or more sensory stimulation tasks for hearing include one or more tasks for listening to one or more sounds to induce fear or relaxation.

9. 7. The digital device for maintaining, optimizing or enhancing a subject's immune system of claim 6, wherein the first vagus nerve stimulation module includes one or more sensory stimulation tasks for touch, and the one or more sensory stimulation tasks for touch include one or more tasks for abdominal breathing, controlling breathing rate, breath holding, cold compresses, dipping the face in cold water, coughing, and skin massage.

10. The digital device for maintaining, optimizing or enhancing a subject's immune system as described in claim 6, wherein the first vagus nerve stimulation module includes one or more sensory stimulation tasks for the sense of smell, and the one or more sensory stimulation tasks for the sense of smell include one or more tasks for relaxing tension.

11. 10. The digital device for maintaining, optimizing or enhancing a subject's immune system of claim 1, wherein the digital device is further configured to emit a scent for aroma therapy.

12. 2. The digital device for maintaining, optimizing or enhancing a subject's immune system as described in claim 1, wherein the first exercise module is provided before the first vagus nerve stimulation module.

13. The digital device for maintaining, optimizing or enhancing a subject's immune system according to claim 2 , wherein the server receives the one or more second tasks from an external reviewer.

14. 1. A method for maintaining, optimizing or enhancing the immune system of a subject, comprising:

11. A method for maintaining, optimizing or enhancing a subject's immune system, comprising the step of providing at least one of a first exercise module or a first vagus nerve stimulation module based on at least one of a processor, each of the first modules including one or more first tasks for the subject to follow.

15. A computer-readable recording medium storing a program for causing a computer to execute the method according to claim 14.

Citation Information

Patent Citations

  • Exercise assisting apparatus

    JP1997238911A

  • Discrimination method of effect by biological stimulation remedy

    JP2005305012A

  • Operating method for application program and electronic device supporting the same

    US20160378608A1